GENEMEDICS APP

GENEMEDICS NUTRITION

Estrogen

Author: Dr. George Shanlikian, M.D.  |   Last Updated: February 5th, 2024

Share This Page

Book a Free Consultation

Estrogen or oestrogen, is the primary female sex hormone that plays a key role in the regulation and development of the female reproductive system as well as secondary sex characteristics. In men, estrogen is also present but in smaller amounts. During puberty, the ovaries start to release estrogen hormones and its levels rise significantly halfway through the menstrual cycle, which triggers the release of an egg. After ovulation, estrogen levels fall back to normal. Aside from the ovaries, estrogen is also produced in the adrenal glands and fat tissues. As a hormone, estrogen usually travels through the bloodstream and interacts with various body tissues to deliver a message.

The estrogen family includes any of a group of chemically similar hormones such as:

  1. Estrone (E1)

E1 is considered as a weak form of estrogen and the only type found in postmenopausal women. It is present in lesser amounts in most body tissues, primarily in fats and muscles.

  1. Estradiol (E2)

E2 is responsible for the development of female secondary sexual characteristics such as breast enlargement, erection of nipples, growth of body hair, widening of the hips, changes in genital structure, and feminine pattern of fat distribution. It also maintains female reproductive tissues such as uterus, vagina, and mammary glands.

  1. Estriol (E3)

E3 is considered as the weakest of estrogens. The levels of E3 are almost undetectable in women who are not pregnant. However, significant amounts of E3 are produced by the placenta during pregnancy.

Potential Health Benefits of Estrogen

  • Maintains Bone Strength and Quality [11-67]
  • Relieves Menopause Symptoms [68-88]
  • Improves Sexual Function [89-113]
  • Reduces Overall Body Fat [116-137]
  • Improves Muscle Mass and Strength [139-170]
  • Improves Mood and Energy Levels [171-190]
  • Reduces Wrinkles and Maintains Younger, Tighter Skin [192-245]
  • Improves Cognitive Function [246-308]
  • Improves Sleep Quality [310-331]
  • Enhances Exercise Performance [332-340]
  • Decreases Urinary Tract Infections (UTI) [341-356]
  • Decreases Risk of Heart Disease [357-403]
  • Improves Cholesterol Profile [404-423]
  • Improves Blood Sugar Levels [424-440]
  • Improves Blood Pressure [441-456]
  • Decreases Risk of Stroke [458-490]
  • Boosts Immune Function [491-507]

Estrogen in Women

Estrogen is crucial to a woman’s reproductive function and cycle. This powerful hormone affects the following body areas:

  • Ovaries: Estrogen is responsible for stimulating the growth of an egg follicle.
  • Vagina: Estrogen stimulates the growth of the vagina and its structures. It also increases vaginal acidity to help fight bacterial infections and it lubricates the vagina.
  • Fallopian tubes: It also stimulates the growth of the muscular walls of the fallopian tubes, and for the muscular contractions that transport the egg cells.
  • Uterus: It helps maintain the lining of the uterus (endometrium) and enhances blood flow and uterine contractions during childbirth. In addition, estrogen also helps get rid of dead tissue in the uterus during menstruation.
  • Cervix: It aids in the fertilization process by enhancing the transport of a sperm cell to an egg.
  • Mammary glands: During adolescence, estrogen stimulates the growth of breast tissue. It also regulates the flow of milk during breastfeeding.

Aside from its key role in maintaining the growth and development of the female reproductive system, estrogen also has the following important functions:

  • During puberty, estrogen slows down the growth of females and enhances the body’s response to insulin.
  • In the liver, estrogen works to regulate cholesterol production.
  • It causes body hair to become finer.
  • It creates the ideal female body frame by making the bones smaller and shorter, the shoulders narrower, and the pelvis broader.
  • It enhances body contour by increasing fat storage around the hips and thighs.
  • It enhances the effects of certain brain chemicals.
  • It gives females a higher-pitched voice by making the voice box smaller and vocal cords shorter.
  • It helps maintain bone strength and quality.
  • It helps regulate body temperature.
  • It improves skin thickness and quality by increasing the production of collagen.
  • It reduces the incidence of acne and oily skin by suppressing the activity of the oil glands.
  • It regulates the brain region that is linked to sexual development.

Estrogen in Men

Men also produce estrogen in smaller amounts. In order for this process to happen, an enzyme called aromatase converts testosterone into estradiol. Research indicates that certain cells in the testis known as Leydig cells, contain the aromatase enzyme and produce some estrogen. [1]The aromatase enzyme is also abundant in the brain and penis. However, as men age, their aromatase levels can sometimes spike, which causes their testosterone to be converted into excess estradiol. [2] This in turn results in low testosterone while spiking estradiol levels. In some men, their aromatase levels are insufficient and suffer from estrogen deficiency. Other men produce abnormally low levels of testosterone that there isn’t enough to convert into estrogen, thus, causing a deficiency in both testosterone and estradiol.

Just like women, men also need estrogen to perform at optimal levels. Estradiol, the predominant form of estrogen, is thought to play a major role in male sexual function. [3] Estradiol in men modulates libido, erectile function, and production of sperm cells. In the brain, estradiol production is increased in areas that regulate sexual arousal. Moreover, several estrogen receptors are distributed throughout the erectile tissues of the penis (corpus cavernosum) with high concentrations found in the nerves, arteries, veins, and other blood vessels.

Estrogen Deficiency

In women over age 40, estrogen levels will significantly decline due to approaching menopause, which is medically known as perimenopause. During this time of transition, a woman’s ovaries will still produce estrogen, however, in smaller amounts. By the time that estrogen production completely stopped, a woman has already reached menopause. This age-related decline in estrogen levels can lead to debilitating signs and symptoms such as:

  • Breast tenderness
  • Brittle bones
  • Cognitive impairment (memory issues, difficulty concentrating, and thinking problems)
  • Difficulty sleeping
  • Frequently missed periods (amenorrhea)
  • Hot flashes
  • Low libido
  • Mood swings
  • Night sweats
  • Painful intercourse
  • Thin, dry, or wrinkled skin

In men, low estrogen levels can also lead to the following signs and symptoms:

  • Anxiety
  • Bone loss
  • Depression
  • Erectile dysfunction
  • Joint pains
  • Fat accumulation
  • Fatigue
  • Irritability
  • Oversleeping or sleeping difficulties
  • Sexual dysfunction
  • Water retention
  • Hot flashes

Aside from the natural process of aging, certain medical conditions, lifestyle choices, and processes can lead to estrogen deficiency. These include:

  • An underactive pituitary gland
  • Anorexia nervosa
  • Breastfeeding
  • Certain medications, such as clomiphene
  • Childbirth
  • Chronic kidney disease
  • Fat and calorie restriction
  • Genetics
  • Ovarian failure
  • Polycystic ovarian syndrome (PCOS)
  • Pregnancy failure
  • Strenuous exercise or training
  • Toxins
  • Turner syndrome

Estrogen Replacement Therapy (ERT)

Over time, the gradual decline in women’s estrogen levels can lead to debilitating signs and symptoms which can ultimately impair one’s quality of life. Women who had their uterus surgically removed (hysterectomy) can also experience these detrimental effects. Fortunately, for those suffering from estrogen deficiency, ERT can be used to increase estrogen levels, alleviate unpleasant symptoms, and improve overall quality of life.

There are different ways ERT is administered. These include:

  • Oral – The oral route is the most frequently utilized method of ERT because it effectively delivers estrogen into the bloodstream. Estrogen tablets are relatively convenient and inexpensive for most women.
  • Transdermal patches (Skin patches) – Skin patches bypass the liver and are recommended for patients who do not respond to estrogen tablets. This route of administration allows the estrogen to be gradually absorbed by the skin.
  • Transdermal gels or creams – This method makes use of a measured amount of gel or cream that is applied on the skin. Application of transdermal gel also allows the estrogen to be gradually absorbed into the bloodstream.
  • Sublingual – This route involves placing estrogen tablets under the tongue. It is absorbed through the lining of the mouth into the blood vessels and then into the bloodstream.
  • Intramuscular injections – Injection of estrogen into the muscles is the most common method of ERT used by many physicians. The hormone is usually mixed with a substance to allow slow release into the bloodstream once injected.
  • Subcutaneous implantations – This method involves implantation of estrogen pellets into the tissue layer between the skin and the muscle at 3-6-month interval. The most commonly used body areas are the abdomen or buttocks.

Potential candidates for ERT usually undergo measurement of estrogen levels first through   comprehensive saliva, blood, urine and serum test. By determining the baseline estrogen levels, the ERT physician will be able to customize a treatment plan that is tailored to the individual needs of the patient.

Proven Health Benefits of ERT

Compelling evidence indicates that restoring estrogen to youthful levels through ERT can help treat and prevent a wide range of medical conditions that can improve one’s quality of life. The following are among the diverse health benefits of ERT:

Maintains Bone Strength and Quality

The body constantly builds and remodels bone. However, after menopause, this process slows down causing women to lose as much as 20% of their bone mass. [4] As a result, postmenopausal women begin to experience osteoporosis, fractures, and other bone disorders.  [5-7] In aging men, low estrogen levels can also increase their risk of developing bone problems.  [8-10] An overwhelming body of clinical evidence suggests that this age-related bone loss can be prevented and treated with ERT:

  1. In both men and women, estrogen regulates bone metabolism and maintains bone formation. [11-13]
  2. In postmenopausal women, low-dose ERT as well as the standard dose ERT is associated with significant reduction in the incidence of osteoporosis and fractures. [14-23]
  3. In postmenopausal women, ERT significantly increases bone mineral density (BMD) of different skeletal sites without any adverse side effects. [24-37]
  4. In postmenopausal women, discontinuation of ERT results in acceleration of bone breakdown, decrease in BMD and eventual loss of anti-fracture efficacy. [38-44]
  5. In early and late postmenopausal women, ERT slows bone breakdown and increases bone BMD at all skeletal sites. [45-46]
  6. In postmenopausal women with osteoporosis and other bone disorders, ERT appears to be safe and effective in increasing bone mass. [47-55]
  7. In humans and animals with bone fractures, ERT accelerates bone healing and prevents further bone breakdown. [56-67]

Relieves Menopause Symptoms

Menopause can bring in a number of physiological changes that can permanently affect a woman’s life. These significant changes include unpleasant symptoms that appear before, during and after the onset of menopause. In order to treat menopause symptoms and replace the declining estrogen levels, most doctors prescribe ERT. There is mounting clinical evidence that ERT is safe and effective in alleviating menopause symptoms:

  1. In healthy women in the perimenopausal transition who are experiencing bothersome symptoms, very-low-dose estrogen therapy (0.3 mg daily) [68-69] or transdermal estradiol (0.025 mg weekly) [70] often is effective in alleviating hot flushes and is associated with minimal side effects.
  2. In postmenopausal women, ERT appears to treat mood swings and other menopause symptoms without any adverse side effects. [71-88]

Improves Sexual Function

When estrogen levels decline, both men and women may experience reduced libido which can ultimately affect their self-confidence as well as quality of life. In women, estrogen deficiency can cause changes to the structures and pH of the vagina, which in turn leads to vaginal health issues such as vaginal dryness, inflammation of vaginal tissues, irritation, and painful sexual intercourse (dyspareunia). In men, low estrogen levels can cause erectile dysfunction and reduced sexual desire. Studies show that undergoing ERT can help treat a wide array of sexual health issues associated with age-related decline in estrogen levels:

  1. In castrated men, elevations in estrogen help maintain some sexual function and do not appear to be harmful. [89]
  2. In male rats, estrogen is considered essential for normal intromission and ejaculatory function. [90]
  3. In postmenopausal women with dyspareunia due to vaginal dryness, ERT restores vaginal cells, pH, lubrication, and blood flow, which in turn improves sexual function.   [91-95]
  4. In pre-menopausal women with estrogen deficiency on hemodialysis, transdermal estradiol treatment is associated with restoration of regular menses and a marked improvement in their sexual function. [96]
  5. In postmenopausal women with decreased libido, ERT improves female sexual functioning by acting on the central nervous system to increase sexual desire. [97-101]
  6. In women who had hysterectomy, ERT is associated with significant improvements in lubrication, orgasm, sexual satisfaction, and general well-being. [102-110]
  7. In postmenopausal women, ERT is associated with higher frequency of sexual activity and improvements in various sexual parameters such as satisfaction, interest, enjoyment, desire, thoughts and fantasies, arousal, responsiveness, and pleasure. [111-113]

Reduces Overall Body Fat

In addition to diet, lifestyle, and genetic factors, the aging process can also contribute to weight gain. In fact, the older we get, the more difficult it is to lose weight. Not only does our metabolism slows down, but also the production of estrogen. In women, the age-related decline in estrogen levels causes their bodies to look for other sources of estrogen, which can be found in fat cells. [114] As a result, their bodies learn to convert more calories into fat, leading to weight gain. In men, the age-related decline in estrogen causes fat accumulation, which in turn results in weight gain. [115] While diet and lifestyle modifications are critical elements to weight loss, there is increasing evidence that restoring estrogen to youthful levels through ERT may help you achieve healthier weight:

  1. In obese menopausal women, three months of ERT significantly reduces weight by increasing energy expenditure. [116]
  2. In healthy postmenopausal women, both intranasal and oral estrogen therapy promotes weight loss by increasing the levels of leptin, a hormone that inhibits hunger. [117-127]
  3. In menopausal women, ERT lowers visceral adipose tissue (fatty tissue) by improving the body’s response to insulin. [128-129]
  4. In postmenopausal women, ERT reduces weight and abdominal fat by lowering cholesterol levels. [130-131]
  5. In postmenopausal women, ERT is associated with a significant reduction in body mass index (BMI). [132-133]
  6. In rats, estrogen prevents weight gain by regulating body adiposity and fat distribution. [134-137]

Improves Muscle Mass and Strength

One of the most undesirable consequences of aging is the loss of muscle mass and strength. Current research suggests that low sex hormone concentration, specifically estrogen, may be among the key mechanisms for muscle wasting (sarcopenia) and weakness. [138] Interestingly, a large body of scientific evidence suggests that restoring estrogen levels through ERT may help diminish age-associated muscle loss and improve overall muscle function:

  1. In postmenopausal women, one-year ERT intervention appears to increase muscle size, vertical jump height and running speed. [139-140]
  2. In older females, ERT increases isometric muscle strength. [141]
  3. In women aged 55–56 years, ERT results in more muscle power, higher vertical jump, faster walking speed, greater lean body mass and less fat mass. [142]
  4. In postmenopausal women, ERT significantly increases muscle mass and improves muscle function by increasing protein synthesis as well as growth factors. [143-146]
  5. In older women with muscle weakness, ERT significantly increases muscle mass, muscle function, muscle force and power generation. [147-149]
  6. In peri- and postmenopausal women, ERT prevents muscle strength loss by improving the function of the existing muscle. [150-153]
  7. In premenopausal and postmenopausal women, ERT significantly increases quadriceps femoris muscle strength. [154-155]
  8. In postmenopausal women, ERT improves performance, mass and composition of various muscle groups in the body. [156-165]
  9. In rodents, estrogen administration reduces muscle structural damage and muscle membrane disruption following potentially damaging exercise. [166-170]

Improves Mood and Energy Levels

Women’s emotional symptoms as they approach menopause vary. Some may experience no symptoms at all while others may have mood swings, depression, anxiety, panic attacks, anger, short temper, snappiness, crying episodes, and irritation. These symptoms can be debilitating and may significantly impair one’s quality of life. In addition, menopausal women suffering from low mood and decreased energy levels may increase their risk of developing mood disorders. Thus, ERT has been proposed as a potentially effective therapeutic strategy for mood disorders experienced during menopause. A number of high quality studies support the mood-enhancing effects of ERT:

  1. In perimenopausal women with DSM-IV-defined major depressive disorder who have minimal response to antidepressants, ERT significantly improves depressive symptoms and scores in the Hamilton Rating Scale for Depression (HAM-D). [171]
  2. In younger mid-life women, 3 months of ERT is associated with significant improvements in mood, everyday memory, working memory, and delayed verbal memory. [172]
  3. In women with postpartum depression, transdermal and sublingual estradiol therapy appears to be safe and effective in alleviating depressive symptoms. [173-174]
  4. In perimenopausal and postmenopausal women, ERT reduces both physical and depressive symptoms while increasing energy levels. [175-187]
  5. In depressed perimenopausal women, estrogen favorably influences neurotransmitters (brain chemicals) involved in mood regulation. [188-190]

Reduces Wrinkles and Maintains Younger, Tighter Skin

During the menopausal years, the age-related decline in skin thickness accelerates by as much as   1.13% per year. [191] The decline in estrogen during this stage results in gradual decrease in collagen, water, and glycosaminoglycans (GAGs) content, which ultimately leads to thinning and sagging of the skin. Fortunately, these age-related skin imperfections can be diminished with ERT. Studies show that estrogen exerts potent anti-aging effect on the skin by reducing wrinkles and improving skin elasticity, which helps maintain a younger, tighter skin:

  1. In postmenopausal women, six months of oral estrogen administration results in an increase in skin thickness, volume, and number of skin cells (keratinocytes). [192-193]
  2. In elderly men and women, application of estrogen on the skin increases keratinocyte proliferation and epidermal thickness after only two weeks. [194]
  3. In postmenopausal women, one year of oral ERT increases dermal thickness by 30% while six months of treatment increases skin collagen by 6.49%. [195-196]
  4. In elderly men and women, application of estrogen on the skin appears to increase levels of type I, II and type III procollagen. [197-211]
  5. In women who were at least five years post-menopause, continuous oral estrogen therapy significantly reduces wrinkles. [212]
  6. Estrogen appears to fight skin aging in both men and women by increasing collagen and moisture content and maintaining skin barrier function. [213-221]
  7. In cultured human epidermal keratinocytes, estrogen stimulates proliferation and DNA synthesis. [222-227]
  8. In cultured human epidermal keratinocytes, estrogen provides protection against photoaging. [228-230]
  9. In postmenopausal women, estrogen administration alleviates skin atrophy (thinning of skin) and xerosis (abnormally dry skin). [231-233]
  10. In postmenopausal women, ERT reverses progressive skin slackness, resulting in younger, tighter skin. [234-235]
  11. In perimenopausal women, ERT reduces the number and depth of wrinkles. [236-238]
  12. In early menopausal women, ERT mitigates age-related changes in tensile properties. [240-241]
  13. In postmenopausal women with sagging skin, both transdermal and oral estrogen preparations increase forearm skin elasticity by 5.2%. [242-243]
  14. In women with wrinkles caused by pregnancy and menopause, ERT use is associated with significant reduction in facial wrinkling as assessed by an eight-point photographic scale. [244]
  15. In postmenopausal women, ERT mitigates the effects of skin aging as assessed by a computerized suction device measuring facial skin distensibility, viscosity and elasticity. [245]

Improves Cognitive Function

Evidence, accumulated over the past several decades, shows that estrogen plays a critical role in the modulation of cognitive function in animals and humans. Modulation begins in the womb when estrogens exert their effect on various brain regions involved in cognitive function. Estrogen influences the nervous system, and this continues through adulthood when its production reaches the highest levels. With aging, estrogen levels gradually decline and contribute to impairment in memory, learning, and thinking skills. Research in basic neuroscience and other clinical research shows that ERT protects against the age-related decline in cognitive function:

  1. In postmenopausal women and women with Alzheimer’s disease (AD), ERT significantly improves memory and attention. [246]
  2. In young surgically menopausal women, injection of 10 mg estradiol every month for 3 months improves verbal memory, abstract reasoning, speed and accuracy. [247]
  3. In healthy postmenopausal women, ERT lowers the risk of Alzheimer’s disease by 29% to 34%. [248-250]
  4. In patients with lesions in the frontal cortex of the brain, ERT use is associated with significant improvements in verbal memory. [251-254]
  5. In patients with age-related cognitive decline, estrogen helps maintain cognitive functions mediated by the frontal lobes. [255-261]
  6. In postmenopausal women, ERT enhances performance on certain tests of working memory and cognitive set-shifting. [262-273]
  7. Neuroimaging studies reveal that estrogen enhances function of the frontal lobe of the brain in women during cognitive challenges. [274-281]
  8. In postmenopausal women, estrogen enhances cognitive function by modulating information processing in the brain. [282-292]
  9. Observational studies of menopausal women taking ERT show that the treatment is associated with better verbal memory, working memory, and visuospatial function, and with a lower risk of dementia. [293-302]
  10. In naturally postmenopausal women, ERT is associated with better verbal fluency, working memory, and psychomotor speed. [303]
  11. Studies show that estrogen exerts its cognition-enhancing efficacy by boosting the regeneration of brain neurons, protecting against programmed cell death (apoptosis), modulating transmission of electrical signals between each neuron, increasing blood flow to the brain, preventing formation of abnormal proteins in the brain (ÎČ-amyloid), and fighting inflammation and free radicals. [304-308]

Improves Sleep Quality

As women transition into menopause, sleep disorders become more common. They may have trouble falling asleep and staying asleep. In fact, studies show that menopausal women spend less time in one of the deepest cycles of sleep known as the rapid eye movement (REM) sleep. [309] This in turn results in fatigue or tiredness upon waking up. Interestingly, several lines of evidence show that ERT improves sleep quality, reduces time to fall asleep and number of times a patient awakens, and increases amount of REM sleep:

  1. In postmenopausal women, ERT significantly improves sleep quality, facilitates falling asleep, and decreases nocturnal restlessness and awakenings. [310-313]
  2. In postmenopausal women with sleep apnea syndrome (SAS), ERT increases REM sleep and decreases the number of waking episodes. [314-317]
  3. In postmenopausal women with mild-to-moderate sleep-disordered breathing (SDB), ERT is associated with significant reduction in measures of sleep-related breathing abnormalities. [318-319]
  4. In women suffering from menopausal symptoms, estrogen administration at a dose of 0.625 mg significantly improves time spent awake after sleep onset and subjective measures of sleep (questionnaires). [320-321]
  5. In postmenopausal women with sleeping difficulties, ERT is associated with significant decrease in hot flushes associated with awakenings, as well as improvement in sleep efficiency and a reduction in the rate of cyclic alternating pattern (EEG marker of unstable sleep). [322]
  6. In menopausal and postmenopausal women, ERT improves sleep by decreasing night time awakenings. [323]
  7. In perimenopausal and postmenopausal women, ERT improves sleep quality by decreasing frequent nighttime awakenings as well as vasomotor symptoms (night sweats, hot flushes and headaches). [324-330]
  8. Estrogen treatment after menopause restores the normal sleep electroencephalogram pattern in postmenopausal women. [331]

Enhances Exercise Performance

With aging, a person’s activity level can significantly decrease because of various changes in body composition. Older persons start to gain weight, lose muscle and bone mass, and become susceptible to a wide array of debilitating diseases that affect their daily routine as well as overall quality of life. Fortunately, aside from diet and lifestyle modifications, restoring estrogen to youthful levels can be beneficial for older people who want to engage in any form of exercise to keep them in shape. By restoring muscle mass and bone quality, studies show that ERT can help enhance one’s exercise performance so that they can become physically active again:

  1. In sedentary overweight adults, ERT appears to improve exercise performance by reducing body fat and improving lipid levels. [332]
  2. In early menopausal women, ERT improves knee extensor strength, vertical jump height, and running speed. [333-334]
  3. In females with estrogen deficiency, ERT lowers risk of stress fracture, thereby allowing them to sustain a high level of physical training. [335]
  4. In older females, ERT is associated with significantly better postural balance. [336]
  5. In postmenopausal females, ERT enhances hand grip strength. [337]
  6. In postmenopausal women with muscle wasting, ERT enhances intense resistance exercises by increasing muscle mass. [338-339]
  7. In healthy postmenopausal women, ERT appears to have beneficial effects on body composition and muscle performance. [340]

Decreases Urinary Tract Infections (UTI)

Postmenopausal women are often vulnerable to bacterial infections such as UTI. During this stage, falling estrogen levels result in deterioration of the urinary tract and vagina, as well as alteration in vaginal flora (bacteria that live inside the vagina). These changes predispose postmenopausal women to recurrent rate of UTIs. A growing body of scientific evidence indicates that ERT can restore vaginal flora and acidic pH to its premenopausal state, thus reducing the prevalence of UTIs in postmenopausal women:

  1. In postmenopausal women with a history of recurrent UTIs, high-dose ERT cures urinary stress and urge incontinence. [341]
  2. In postmenopausal women with urogenital complaints related to estrogen deficiency, low-potency estrogens do not only improve urogenital complaints effectively but also prevent recurrent UTI. [342]
  3. Estrogen prevents UTI by stimulating the proliferation of lactobacillus in the vaginal epithelium, reducing pH, preventing vaginal colonization with Enterobacteriaceae (causative agent of UTI), and maintaining vaginal structure. [343]
  4. In women with atrophic vaginitis (chronic and progressive inflammation of the vagina), use of estriol orally or vaginally is safe and improves urogenital complaints. [344-345]
  5. In elderly women, vaginal estrogen treatment for one month dramatically reduces the incidence of UTI by increasing Lactobacilli and restoring vaginal pH. [346-347]
  6. In women without liver disease, application of 0.5 mg of estriol cream produces similar beneficial effects with that of oral estriol in treating UTI. [348-349]
  7. In menopausal women with recurrent UTI, estrogen stimulates the production of the body’s own antibiotic and strengthens the cells in the urinary tract. [350]
  8. In postmenopausal women with recurrent UTI, use of vaginal estrogen ring for nine months reduces the incidence of UTI by 45%.[351]
  9. Oral estrogen administration at a dose of 3 mg of daily for 8 weeks and 1 mg thereafter also reduces the incidence of UTI in postmenopausal women. [352]
  10. In postmenopausal incontinent women, short duration (3-6 months) of ERT has significant benefits on UTI, overactive bladder symptoms, and incontinence. [353-354]
  11. In postmenopausal women with recurrent UTI, ERT is more effective than antibiotics at alleviating urinary symptoms. [355]
  12. If administered preoperatively, estrogen can improve outcomes of incontinence repair procedures, thereby preventing UTI. [356]

Decreases Risk of Heart Disease

The age-related decline in estrogen increases one’s risk of heart disease. This is because estrogen is believed to play a crucial role in the maintenance of a healthy heart by keeping blood vessels flexible, thereby improving the heart’s pumping power and overall blood circulation. In addition, falling estrogen levels increase blood pressure, blood sugar and cholesterol levels – all of which are major risk factors for heart disease! Recent research adds to the evidence that estrogen protects against heart attack and other adverse cardiovascular events:

  1. Transdermal ERT may actually reduce the risk of heart disease among smokers and obese patients. [357-358]
  2. Results from observational studies assessing the safety and benefit of ERT in young menopausal women show that local administration of estrogen in the form of vaginal creams, vaginal rings and transdermal patches is not associated with any adverse cardiovascular events. [359-360]
  3. Observational studies also show that postmenopausal women who receive ERT have a lower rate of cardiovascular disease and cardiac death than those not receiving ERT. [361-362]
  4. Estrogen helps activate nitric oxide, which in turn dilates the blood vessels of the heart and improves blood circulation. [363-366]
  5. In the heart, estrogen receptors preserve cardiac function and protect against tissue damage caused by lack of oxygen (ischemia). [367-368]
  6. Estrogen protects against heart disease by reducing oxidative stress, which is one of the major causes of heart failure. [369-372]
  7. Estrogen has a profound antiapoptotic (prevents cells death) and pro-survival effect on heart muscle cells (cardiomyocytes). [373-374]
  8. Estrogen protects against heart disease by reducing inflammatory markers. [375-376]
  9. Estrogen promotes migration of stem cells into the injured heart muscle after ischemia, thereby improving endothelial and myocardial function. [377-379]
  10. ERT decreases the risk of cardiovascular disease (CVD) and reduces mortality in postmenopausal women with heart disease. [380-381]
  11. ERT use early after menopause significantly reduces risk of mortality, heart failure, or myocardial infarction. [382-386]
  12. ERT use in postmenopausal women is associated with the cessation and potentially with the reversal of the progression of carotid artery atherosclerosis (plaque build-up) as assessed by ultrasonography. [387]
  13. Estrogen exerts its antiatherogenic activity (fights plaque build-up) by improving cholesterol levels and preventing oxidation in the walls of the blood vessels of the heart.      [388-395]
  14. In postmenopausal women with stable angina, atypical chest pain, or an abnormal exercise electrocardiogram (ECG), intravenous administration of estrogen significantly improves blood flow to the heart. [396-397]
  15. In postmenopausal women, ERT significantly increases brachial arterial blood flow, which is an independent marker of blood circulation in the heart. [398-403]

Improves Cholesterol Profile

Cholesterol levels spike in men and women with advancing age. For women, however, this age-related change is striking at the menopausal transition stage. With falling estrogen levels, high-density lipoprotein (HDL) cholesterol, also known as the “good cholesterol”, starts to decline. On the other hand, the age-related decline in estrogen levels increases low-density lipoprotein (LDL) cholesterol, also known as the “bad cholesterol”. These changes in cholesterol levels are very detrimental to health because it drastically increases one’s risk of developing fatal medical conditions such as heart disease, stroke, cancer, diabetes, and hypertension. While diet and lifestyle modifications can be beneficial in improving cholesterol profile, there is strong evidence that ERT may also help normalize cholesterol levels:

  1. In healthy postmenopausal women, oral estrogen supplementation increases HDL cholesterol levels by 15-18%. [404]
  2. In healthy postmenopausal women who had surgical removal of the uterus, both oral and transdermal estradiol for 4 weeks increase HDL by 7.1%. [405-406]
  3. In healthy premenopausal women, ERT increases HDL and decreases LDL levels without any adverse side effects. [407-418]
  4. In postmenopausal women with elevated cholesterol levels, ERT produces significant and therapeutic reductions in LDL cholesterol. [419-421]
  5. Oral estrogen administration for 6 months significantly increases HDL and decreases LDL in menopausal women, making it the most effective route. [422-423]

Improves Blood Sugar Levels

Estrogen helps optimize the action of insulin, the hormone that stabilizes blood sugar levels. Consequently, the age-related decline in estrogen may lead to insulin resistance, a condition in which the body doesn’t respond to the effects of insulin. Falling estrogen levels can also impair the function of insulin, resulting in sudden spikes in blood sugar levels. Studies show that by restoring estrogen to youthful levels, blood sugar levels can be normalized, thus, preventing chronic medical conditions such as diabetes:

  1. In postmenopausal women with type 2 diabetes, ERT is associated with statistically significant increase in insulin sensitivity (a condition in which small amount of insulin is needed to keep blood sugar levels in the normal range). [424]
  2. In diabetic women, ERT significantly lowers hemoglobin A1c, a three-month average measure of blood sugar level. [425-430]
  3. In diabetic women, ERT is associated with better glycemic control. [431]
  4. In postmenopausal women, low-dose combined ERT is associated with decreased risk of developing diabetes and better diabetic control. [432]
  5. In non-diabetic women, the prescription of ERT improves mortality by stabilizing blood sugar levels. [433]
  6. Postmenopausal estrogen use is associated with lower fasting glucose. [434]
  7. In postmenopausal women with type 2 diabetes, ERT use is associated with better blood sugar control and improved insulin sensitivity. [435-440]

Improves Blood Pressure

During menopause, women lose hormone protection against a wide array of fatal medical conditions. Among them is high blood pressure or hypertension, which is highly prevalent in menopausal women. In addition to this, the age-related decline in estrogen levels puts them more at risk since estrogen engages several mechanisms that protect against hypertension. An overwhelming body of clinical trials supports the antihypertensive effect of estrogen:

  1. Transdermal delivery of estrogen appears to have blood pressure-lowering effect in postmenopausal women and may be a safer alternative in hypertensive women. [441]
  2. In postmenopausal women with arterial hypertension, one-year ERT improves circadian blood pressure pattern by inhibiting age-related rigidity of large arteries. [442]
  3. In women with elevated resting blood pressure and positive family history of congestive heart failure (CHD), ERT inhibits exaggerated BP reactivity to stress. [443]
  4. In postmenopausal women, transdermal ERT improves 24-hour blood pressure profile. [444]
  5. In hypertensive postmenopausal women, ERT is associated with a lower diastolic blood pressure and decrease use of antihypertensive drugs. [445]
  6. In menopausal women with mild to moderate hypertension, ERT use is associated with lower blood pressure. [446]
  7. In postmenopausal women, ERT use is associated with lower pulse wave velocity (PWV), a measure of arterial stiffness. [447-450]
  8. ERT improves blood pressure by counteracting arterial distensibility and increasing nitric oxide levels which both lead to widening of blood vessels. [451-456]

Decreases Risk of Stroke

Although middle-aged women have a lower incidence of stroke than men, their risk significantly increase by as much as 50% in the decade after menopause. [457] This may be due to the fact that estrogen deficiency during the postmenopausal period leads to obesity and increases in blood pressure, cholesterol and blood sugar levels – all of which are major risk factors of stroke. Interestingly, there is robust clinical evidence that ERT may actually protect against different types of stroke:

  1. In postmenopausal women, ERT use is associated with a decrease in the incidence of stroke, suggesting that the treatment is safe and effective. [458]
  2. In middle-aged and older women, researchers found that ERT decreases risk of total stroke during 10.5 years follow-up. [459]
  3. In younger postmenopausal women, ERT is associated with lower prevalence of stroke. [460]
  4. Studies indicate a reduced risk of stroke and its consequent mortality among estrogen users. [461]
  5. In younger postmenopausal women with normal blood pressure (50-59 years), there is a reduced risk of stroke associated with ERT use, particularly when lower doses are prescribed soon after menopause. [462]
  6. In women aged 50-79 years, transdermal ERT reduces stroke risk by 25%. [463]
  7. In users of low-dose ERT, the treatment significantly reduces the risk of stroke without any adverse side effects. [464]
  8. In postmenopausal women without personal history of cardiovascular disease or contraindication to hormone therapy, short-term ERT use is associated with lower risk of stroke and is considered safe. [465]
  9. In postmenopausal women, ERT protects against stroke by increasing membrane fluidity of red blood cells and improving the rigidity of cell membranes via activation of nitric oxide. [466]
  10. Experimental evidence suggests that estradiol can protect the brain from stroke and that surgical removal of the ovaries removes this neuroprotective effect. [467-468]
  11. In animals, estradiol administration decreases infarct size (extent of tissue injury) in the brain. [469]
  12. In male adult rats, higher blood estradiol protects against ischemic injury. [470]
  13. In rats, administration of estrogen protects against stroke by reducing the levels of inflammatory substances. [471-490]

Boosts Immune Function

With aging, estrogen levels along with immune function start to decline predisposing a person to wide array of diseases. This is because sex hormones such as estrogen are known as the “master regulators” of the immune system. Therefore, restoring estrogen to youthful levels through ERT can significantly boost immune function and prevent fatal illnesses related with advancing age. An increasing number of scientific evidence supports the “immune-boosting” effect of estrogen:

  1. In patients with early breast cancer, ERT does not increase either the risk of recurrence or of death. [491]
  2. In patients with rheumatoid arthritis and systemic lupus erythematosus, ERT is associated with decreased risk of disease flare and improvement in disease activity. [492]
  3. In perimenopausal women, ERT regulates immune function by increasing immune cells such as CD8+ cells. [493]
  4. In postmenopausal women, ERT reverses immune alterations associated with normal aging. [494]
  5. In postmenopausal women, ERT restores immune balance by enhancing antibody-mediated immunity. [495]
  6. The use of ERT alone in female patients is associated with a significant reduction in lung cancer risk and related death. [496-499]
  7. Estradiol reduces programmed cell death (apoptosis) of immature B cells of the immune system. [500]
  8. Estrogen indirectly boosts the immune function by modulating the levels of growth hormone, prolactin, or thymosin. [501]
  9. In postmenopausal women with arthritis, ERT significantly decreases disease activity and signs of inflammation. [502]
  10. In postmenopausal women, ERT reverses the deleterious effects of aging on the immune system by increasing the number of B-cells and improving T-cell function. [503]
  11. In postmenopausal women, ERT improves immune function by reducing elevated blood levels of the pro-inflammatory cytokines TNF-α, IFN-γ and IL-6. [504-507]

The Women’s Health Initiative (WHI): What Went Wrong?

By the mid-1990s, ERT had become one of the most widely prescribed medications for women in their menopausal period. Several observational studies have shown that women who were given ERT had lower risk of heart disease. However, in 2002, the results of the large Women’s Health Initiative (WHI) study have been both influential and controversial. This study involved 27,347 U.S. women ages 50-79 – 16,608 of them had a uterus and were given estrogen-plus-progestin while 10,739 had no uterus and were given estrogen alone. Unfortunately, the study concluded that ERT can increase one’s risk of developing breast cancer, heart disease, stroke, blood clots, and overall harm, which led to early stoppage of the clinical trial. [508] While the WHI study is considered as one of the largest clinical trials assessing the safety and efficacy of estrogen on women, several high quality studies do not agree with its results because of the following reasons:

  1. The hazard ratio (HR) of the WHI study did not reach statistical significance. The authors of the WHI study reported a “significant” hazard ratio for coronary heart disease (CHD), breast cancer, blood clots, and stroke. However, other health experts who have carefully examined the WHI study suggest that the conclusions drawn were incorrect because their hazard ratio for each potential health hazard did not reach statistical significance and was based on unadjusted risk hazards. [509-510]
  2. The WHI study does not even qualify as a randomized placebo-controlled study.

The reasons for this are the following: [511-515]

  1. After randomization, the women were free to decide whether to continue their assigned treatment or whether to undergo diagnostic procedures.
  2. Almost 50% of the women were aware of their treatment.
  3. The participants received several warnings regarding increased risks of heart disease, stroke and blood clots during the study.
  4. Post-hoc analyses suggest no increase in CHD in women starting estrogen treatment within 10 years of menopause. Post-hoc analyses are analyses that were not pre-planned and were conducted as additional analyses after completion of the experiment or clinical trial. Authors of the WHI study concluded that estrogen therapy had no beneficial effect on the risk of CHD and such treatment might increase CHD risk. On the contrary, post-hoc analyses found that there was no increase in CHD risk in women starting estrogen treatment within 10 years of menopause. [516]
  5. The authors of the WHI study did not mention the other significant benefits of estrogen treatment among the participants. The authors only reported increased risk of breast cancer, heart attacks, stroke and blood clotting among women receiving estrogen therapy. They did not mention that the treatment “significantly” decreased the risk of colon cancer and hip fractures among the participants. [517]
  6. There are some health factors that might have altered the outcome of the WHI study. The participants in the WHI study has an average BMI of 28 (overweight), one-third were hypertensive and one-half were smokers, suggesting that these factors might have significantly altered the outcome of the clinical trial. [518]   
  7. The women in the WHI study were 12-15 years past the onset of menopause. This means that the participants were without their pre-menopausal estrogen levels long enough to bring about various changes in bodily functions. For instance, when estrogen is no longer secreted at menopause, this causes a decline in bone mineral density, thereby increasing a person’s risk of fractures and osteoporosis. In addition, estrogen is crucial for maintaining normal structure and function of the blood vascular system. Once a disease has already afflicted this system, ERT will not likely reverse its negative effects. [519] Therefore, ERT should be used as preventive, not corrective therapy; therefore, administration of estrogen should start during the menopausal transition and not 12-15 years past the onset of menopause.
  8. The WHI study actually found beneficial effects of estrogen on heart disease, breast cancer and diabetes risk as well as improvements in menopausal symptoms, joint pain and physical functioning. The authors of the WHI study found the following beneficial effects of estrogen on various health hazards: [520]
  • Diabetes risk decreased by 14-19%.
  • For every 10,000 women taking estrogen-alone over a one-year period, there were 11 fewer diagnoses of CHD among women in their 50s and a 40% reduction in heart attack compared to placebo when examined over the whole 13-year time period.
  • In the estrogen-alone trial, the participants had a reduced risk of breast cancer (21%) over the 13-year follow-up. The reduction in breast cancer risk even persisted after stopping the treatment.
  • In women ages 50-54 years taking estrogen only, menopausal symptoms such as hot flashes and night sweats were decreased by 28%.
  • Joint pain decreased during estrogen treatment.
  • Over the 13-year follow-up, the rates of hip fractures were still lower in women who received estrogen.
  • Physical functioning improved in the estrogen-alone group.
  • There were reduced risks of overall illness and death in women taking estrogen-alone in their 50s
Share This Page

Reference

  1. Abney TO. The potential roles of estrogens in regulating Leydig cell development and function: a review. Steroids. 1999; 64(9):610-7.

  2. De Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reproductive Biology and Endocrinology : RB&E. 2011;9:93. doi:10.1186/1477-7827-9-93.

  3. Schulster M, Bernie AM, Ramasamy R. The role of estradiol in male reproductive function. Asian Journal of Andrology. 2016;18(3):435-440. doi:10.4103/1008-682X.173932.

  4. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women. The Journal of Clinical Endocrinology and Metabolism. 2008;93(3):861-868. doi:10.1210/jc.2007-1876.

  5. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000;21:115–137.

  6. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in ageing men. J. Bone Miner. Res. 1998;13:763–773.

  7. Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J. Bone Miner. Res. 1997;12:498–508.

  8. Katznelson L, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 1996;81:4358–4365.

  9. Danie01010ll HW. Osteoporosis after orchiectomy for prostate cancer. J. Urol. 1997;157:439–444. 01010.

  10. Falahati-Nini A, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 2000;106:1553–1560.

  11. Khosla S, Melton LJ, Riggs BL. Estrogens and bone health in men. Calcified tissue international. 2001; 69(4):189-92.

  12. Cauley JA. Estrogen and bone health in men and women. Steroids. 2015; 99(Pt A):11-5.

  13. Carlsen CG, Soerensen TH, Eriksen EF. Prevalence of low serum estradiol levels in male osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2000; 11(8):697-701.

  14. Gambacciani M, Vacca F. Postmenopausal osteoporosis and hormone replacement therapy. Minerva medica. 2004; 95(6):507-20.

  15. Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Przegla̜d Menopauzalny = Menopause Review. 2014;13(4):213-220. doi:10.5114/pm.2014.44996.

  16. Shulman LP. Transdermal hormone therapy and bone health. Clinical Interventions in Aging. 2008;3(1):51-54.

  17. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. JAMA. 2003;290:1729–38.

  18. Wimalawansa SJ. Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2000; 3(2):187-201.

  19. Thorneycroft IH. The role of estrogen replacement therapy in the prevention of osteoporosis. American journal of obstetrics and gynecology. 1989; 160(5 Pt 2):1306-10.

  20. Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, DeStavola BL, Rose S, Dowell A, Wilkes HC, Darbyshire JH, Meade TW 2007 Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335:239-250.

  21. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D 2002 Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58-66.

  22. Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1997; 7 Suppl 1:S3-7.

  23. Patel S. Effect of hormone replacement therapy on bone density in a patient with severe osteoporosis caused by anorexia nervosa. Annals of the Rheumatic Diseases. 1999;58(1):66.

  24. Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Archives of internal medicine. 2000; 160(14):2161-6.

  25. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Annals of internal medicine. 1996; 125(5):360-8.

  26. Simsek M, Cetin Z, Bilgen T, Taskin O, Luleci G, Keser I. Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism. The journal of obstetrics and gynaecology research. 2008; 34(1):73-7.

  27. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996; 276(17):1389-96.

  28. Margerison C, Paton LM, Nowson CA, Ferdous HS, Kaymakci B, Wark JD. Hormone replacement therapy and bone mineral density: a co-twin approach. Menopause (New York, N.Y.). ; 9(6):436-42.

  29. Kim HJ, Oh YK, Lee JS, Lee D-Y, Choi D, Yoon B-K. Effect of Transdermal Estrogen Therapy on Bone Mineral Density in Postmenopausal Korean Women. Journal of Menopausal Medicine. 2014;20(3):111-117. doi:10.6118/jmm.2014.20.3.111.

  30. Abdi F, Mobedi H, Bayat F, Mosaffa N, Dolatian M, Ramezani Tehrani F. The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis. Iranian Journal of Pharmaceutical Research : IJPR. 2017;16(1):380-389.

  31. Moore M, Bracker M, Sartoris D, Saltman P, Strause L. Long-term estrogen replacement therapy in postmenopausal women sustains vertebral bone mineral density. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1990; 5(6):659-64.

  32. Al-Azzawi F, Lees B, Thompson J, Stevenson JC. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Menopause. 2005;12(3):331-339.

  33. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104(3):443-451.

  34. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab. 2013;98(2):E249-E257.

  35. Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause. 2005;12(6):741-748.

  36. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003;290(8):1042-1048.

  37. Mizunuma H, Taketani Y, Ohta H, et al. Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis. Climacteric. 2010;13(1):72-83.

  38. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729-1738.

  39. Trémollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2001; 12(5):385-90.

  40. Bachelot A, Nicolas C, Gricourt S, et al. Poor Compliance to Hormone Therapy and Decreased Bone Mineral Density in Women with Premature Ovarian Insufficiency. Williams BO, ed. PLoS ONE. 2016;11(12):e0164638. doi:10.1371/journal.pone.0164638.

  41. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone. 2002; 30(4):599-603.

  42. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4914-23.

  43. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause (New York, NY). 2011;18(11):1172-1177. doi:10.1097/gme.0b013e31821b01c7.

  44. Gallagher JC et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002 Nov; 87:4914-23.

  45. Bjarnason NH, Hassager C, Christiansen C 1998 Postmenopausal bone remodelling and hormone replacement. Climacteric 1:72-79.

  46. Torgerson DJ, Bell-Syer SE 2001 Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285:2891-2897.

  47. Castelo-Branco C, Rovira M, Pons F. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas. 1996; 23(3):307-12.

  48. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis and rheumatism. 1994; 37(10):1499-505.

  49. Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone. 2003; 33(1):159-66.

  50. Meschia M, Brincat M, Barbacini P, Maini MC, Marri R, Crosignani PG. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. European journal of obstetrics, gynecology, and reproductive biology. 1992; 47(1):53-7.

  51. Hohenhaus MH, McGarry KA, Col NF. Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option? Drugs. 2007; 67(16):2311-21.

  52. Cheng S, SipilÀ S, Taaffe DR, Puolakka J, Suominen H. Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone. 2002; 31(1):126-35.

  53. Deng HW, Li J, Li JL. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Human genetics. 1998; 103(5):576-85.

  54. Eviö S, Tiitinen A, Laitinen K, Ylikorkala O, VÀlimÀki MJ. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. The Journal of clinical endocrinology and metabolism. 2004; 89(2):626-31.

  55. TiraƟ MB, Noyan V, Yildiz A, Yildirim M, Daya S. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Human reproduction (Oxford, England). 2000; 15(10):2087-92.

  56. Nociti FH, Sallum AW, Sallum EA, Duarte PM. Effect of estrogen replacement and calcitonin therapies on bone around titanium implants placed in ovariectomized rats: a histometric study. The International journal of oral & maxillofacial implants. ; 17(6):786-92.

  57. de Almeida JM, Bosco AF, Faleiros PL. Effects of oestrogen deficiency and 17ÎČ-estradiol therapy on bone healing in calvarial critical size defects treated with bovine bone graft. Archives of oral biology. 2015; 60(4):631-41.

  58. McCarthy TL, Centrella M. Prostaglandin dependent control of an endogenous estrogen receptor agonist by osteoblasts. Journal of cellular physiology. 2015; 230(5):1104-14.

  59. Wei L, Ke J, Prasadam I. A comparative study of Sr-incorporated mesoporous bioactive glass scaffolds for regeneration of osteopenic bone defects. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014; 25(8):2089-96.

  60. Ibrahim N’, Mohamad S, Mohamed N, Shuid AN. Experimental fracture protocols in assessments of potential agents for osteoporotic fracture healing using rodent models. Current drug targets. 2013; 14(14):1642-50.

  61. Estai MA, Suhaimi FH, Das S. Piper sarmentosum enhances fracture healing in ovariectomized osteoporotic rats: a radiological study. Clinics (Sao Paulo, Brazil). 2011; 66(5):865-72.

  62. Luvizuto ER, Dias SS, Okamoto T, Dornelles RC, Okamoto R. Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats. Archives of oral biology. 2011; 56(10):984-90.

  63. Kolios L, Sehmisch S, Daub F. Equol but not genistein improves early metaphyseal fracture healing in osteoporotic rats. Planta medica. 2009; 75(5):459-65.

  64. Kovacs EJ. Aging, traumatic injury, and estrogen treatment. Experimental gerontology. 2005; 40(7):549-55.

  65. Qi MC, Zhou XQ, Hu J. Oestrogen replacement therapy promotes bone healing around dental implants in osteoporotic rats. International journal of oral and maxillofacial surgery. 2004; 33(3):279-85.

  66. Beil FT, Barvencik F, Gebauer M. Effects of estrogen on fracture healing in mice. The Journal of trauma. 2010; 69(5):1259-65.

  67. Vaananen HK, HÀrkönen PL. Estrogen and bone metabolism. Maturitas. 1996; 23 Suppl:S65-9.

  68. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;75:1065–79.

  69. Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, et al. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997;157:2609–15.

  70. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. Obstet Gynecol. 1999;94:330–6.

  71. Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-based approach. International Journal of Women’s Health. 2014;6:47-57. doi:10.2147/IJWH.S38342.

  72. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. Journal of the American Academy of Nurse Practitioners. 2007; 19(12):635-41.

  73. Roberts PJ. The menopause and hormone replacement therapy: views of women in general practice receiving hormone replacement therapy. The British Journal of General Practice. 1991;41(351):421-424.

  74. Shook LL. An Update on Hormone Replacement Therapy: Health and Medicine for Women: A Multidisciplinary, Evidence-Based Review of Mid-Life Health Concerns. The Yale Journal of Biology and Medicine. 2011;84(1):39-42.

  75. Yasui T, Uemura H, Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. The journal of medical investigation : JMI. 2003; 50(3-4):136-45.

  76. Birge SJ. The use of estrogen in older women. Clinics in geriatric medicine. 2003; 19(3):617-27, viii.

  77. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Annals of internal medicine. 1999; 131(8):605-16.

  78. Griffiths F, Convery B. Women’s use of hormone replacement therapy for relief of menopausal symptoms, for prevention of osteoporosis, and after hysterectomy. The British Journal of General Practice. 1995;45(396):355-358.

  79. Dalal PK, Agarwal M. Postmenopausal syndrome. Indian Journal of Psychiatry. 2015;57(Suppl 2):S222-S232. doi:10.4103/0019-5545.161483.

  80. Parry BL. Optimal management of perimenopausal depression. International Journal of Women’s Health. 2010;2:143-151.

  81. Yazici K, Pata O, Yazici A, AktaƟ A, Tot S, Kanik A. [The effects of hormone replacement therapy in menopause on symptoms of anxiety and depression]. Turk psikiyatri dergisi = Turkish journal of psychiatry. 2003; 14(2):101-5.

  82. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. Journal of the American Academy of Nurse Practitioners. 2007; 19(12):635-41.

  83. Beckmann MW, Jap D, Djahansouzi S. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology. 2001; 60(3):199-206.

  84. Björn I, BÀckström T, Lalos A, Sundström-Poromaa I. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric : the journal of the International Menopause Society. 2006; 9(4):290-7.

  85. Clayton AH, Ninan PT. Depression or Menopause? Presentation and Management of Major Depressive Disorder in Perimenopausal and Postmenopausal Women. Primary Care Companion to The Journal of Clinical Psychiatry. 2010;12(1):PCC.08r00747. doi:10.4088/PCC.08r00747blu.

  86. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstetrics and gynecology. 2010; 115(4):839-55.

  87. Mahmud K. Natural hormone therapy for menopause. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2010; 26(2):81-5.

  88. Bolton JL. Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. Chemical Research in Toxicology. 2016;29(10):1583-1590. doi:10.1021/acs.chemrestox.6b00272.

  89. Kacker R, Traish AM, Morgentaler A. Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. The journal of sexual medicine. 2012; 9(6):1681-96.

  90. Ogawa S, Washburn TF, Taylor J, Lubahn DB, Korach KS, et al. Modifications of testosterone-dependent behaviors by estrogen receptor-alpha gene disruption in male mice. Endocrinology. 1998;139:5058–69.

  91. Sarrel PM. Effects of hormone replacement therapy on sexual psychophysiology and behavior in postmenopause. Journal of women’s health & gender-based medicine. 2000; 9 Suppl 1:S25-32.

  92. Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: effect of estrogen and progestogen. Obstetrics & Gynecology. 1980;56(3):316–317.

  93. Nathorst-Böös J, Wiklund I, Mattsson LÅ, Sandin K, Schoultz BV. Is sexual life influenced by transdermal estrogen therapy?: A double blind placebo controlled study in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica. 1993;72(8):656–660.

  94. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women’s Health Across the Nation (SWAN) Menopause. 2005;12(4):385–398.

  95. Omu AE, al-Qattan N. Effects of hormone replacement therapy on sexuality in postmenopausal women in a mideast country. The journal of obstetrics and gynaecology research. 1997; 23(2):157-64.

  96. Matuszkiewicz-Rowiñska J, SkĂłrzewska K, Radowicki S. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association. 1999; 14(5):1238-43.

  97. Dow MGT, Hart DM, Forrest CA. Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study. British Journal of Obstetrics & Gynaecology. 1983;90(4):361–366.

  98. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas. 1995;21(3):227–236.

  99. Dennerstein L, Burrows GD, Wood C, Hyman G. Hormones and sexuality: effect of estrogen and progestogen. Obstetrics & Gynecology. 1980;56(3):316–317.

  100. Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 1991;72(2):336–343.

  101. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosomatic Medicine. 1987;49(4):397–409.

  102. Kotz K, Alexander JL, Dennerstein L. Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women. Journal of women’s health (2002). 2006; 15(8):898-908.

  103. McPherson K, Herbert A, Judge A. Psychosexual health 5 years after hysterectomy: population-based comparison with endometrial ablation for dysfunctional uterine bleeding. Health expectations : an international journal of public participation in health care and health policy. 2005; 8(3):234-43.

  104. Collins A, Landgren BM. Reproductive health, use of estrogen and experience of symptoms in perimenopausal women: a population-based study. Maturitas. 1994; 20(2-3):101-11.

  105. Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric : the journal of the International Menopause Society. 2006; 9(5):325-35.

  106. Lonnée-Hoffmann R, Pinas I. Effects of Hysterectomy on Sexual Function. Current Sexual Health Reports. 2014;6(4):244-251. doi:10.1007/s11930-014-0029-3.

  107. Ambler DR, Bieber EJ, Diamond MP. Sexual Function in Elderly Women: A Review of Current Literature. Reviews in Obstetrics and Gynecology. 2012;5(1):16-27.

  108. Blumel JE, Bravo F, Recavarren M, SarrĂĄ S. [Sexual function in postmenopausal women using hormone replacement therapy]. Revista medica de Chile. 2003; 131(11):1251-5.

  109. Nathorst-Böös J, von Schoultz B, Carlström K. Elective ovarian removal and estrogen replacement therapy–effects on sexual life, psychological well-being and androgen status. Journal of psychosomatic obstetrics and gynaecology. 1993; 14(4):283-93.

  110. Dennerstein L, Burrows GD. Hormone replacement therapy and sexuality in women. Clinics in endocrinology and metabolism. 1982; 11(3):661-79.

  111. de Ligniùres B, Weill E, Mauvais-Jarvis P, Knellesen S, Deutsch E. [Interactive relations between sexual behavior and post-menopausal replacement hormone therapy: a survey]. Revue francaise de gynecologie et d’obstetrique. 1990; 85(11):581-6.

  112. Borissova AM, Kovatcheva R, Shinkov A, Vukov M. A study of the psychological status and sexuality in middle-aged Bulgarian women: significance of the hormone replacement therapy (HRT). Maturitas. 2001; 39(2):177-83.

  113. Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause (New York, N.Y.). ; 11(6 Pt 2):749-65.

  114. Lizcano F, GuzmĂĄn G. Estrogen Deficiency and the Origin of Obesity during Menopause. BioMed Research International. 2014;2014:757461. doi:10.1155/2014/757461.

  115. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. The New England journal of medicine. 2013; 369(25):2457.

  116. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas. 1999; 32(3):147-53.

  117. YĂŒksel H, OdabaƟi AR, Demircan S, et al. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition. Gynecol Endocrinol. 2006;22(7):381–387.

  118. Kristensen K, Pedersen SB, Vestergaard P, Mosekilde L, Richelsen B. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women. J Endocrinol. 1999;163(1):55–62.

  119. Lambrinoudaki IV, Christodoulakos GE, Panoulis CP, et al. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. Maturitas. 2004;48(2):107–113.

  120. Castelo-Branco C, Palacios S, Vázquez F, et al. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertil Steril. 2007;88(2):383–389.

  121. Tommaselli GA, Di Carlo C, Di Spiezio Sardo A, et al. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. Menopause. 2006;13(4):660–668.

  122. Di Carlo C, Tommaselli GA, Sammartino A, Bifulco G, Nasti A, Nappi C. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause. 2004;11(4):466–473.

  123. Dedeoğlu EN, Erenus M, YörĂŒk P. Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertil Steril. 2009;91(2):425–431.

  124. Laivuori H, Koistinen HA, Karonen SL, Cacciatore B, Ylikorkala O. Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. Hum Reprod. 2001;16(8):1632–1635.

  125. Konukoglu D, Serin O, Ercan M. Plasma leptin levels in obese and non-obese postmenopausal women before and after hormone replacement therapy. Maturitas. 2000;36(3):203–207.

  126. Petzel M, Stejskal D, Jedelsky L, Kadalova L, Safarcik K. The influence of estradiole and tibolone administration on leptin levels in women with surgically induced menopause. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(1):101–105.

  127. Nar A, Demirtas E, Ayhan A, Gurlek A. Effects of bilateral ovariectomy and estrogen replacement therapy on serum leptin, sex hormone binding globulin and insulin like growth factor-I levels. Gynecol Endocrinol. 2009;25(12):773–778.

  128. Gormsen LC, Host C, Hjerrild BE, et al. Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. European Journal of Endocrinology. 2012;167:543–551.

  129. Munoz J, Derstine A, Gower BA. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement. Obesity Research. 2002;10(6):424–431.

  130. Sumino H, Ichikawa S, Yoshida A. Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2003; 27(9):1044-51.

  131. Van Pelt RE, Gozansky WS, Wolfe P, et al. A randomized trial of estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes. Obesity (Silver Spring, Md). 2014;22(4):1024-1031. doi:10.1002/oby.20653.

  132. Straub RH, Hense HW, Andus T, Schölmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. The Journal of clinical endocrinology and metabolism. 2000; 85(3):1340-4.

  133. Cortés-Prieto J, Vicente-Hernanz ML, Cortés-García A, Keller J, del Rio RC, Brita-Paja Segoviano JL. Hormone replacement therapy: evolution of body mass index, bone mineral density, and lipid profile. Hormone molecular biology and clinical investigation. 2013; 13(2):19-40.

  134. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol. 1985;8(2):128–133.

  135. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(12):5925–5930.

  136. Musatov S, Chen W, Pfaff DW, Mobbs CV, Yang XJ, Clegg DJ, Kaplitt MG, Ogawa S. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(7):2501–2506.

  137. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(23):12729–12734.

  138. SipilÀ S, Narici M, Kjaer M. Sex hormones and skeletal muscle weakness. Biogerontology. 2013; 14(3):231-45.

  139. Sipila S, Taffe DR, Cheng S, et al. Effects of hormone replacement therapy and high impact physical exercise on skeletal muscle in post-menopausal women: a randomized control trial. Clin Sci. 2001;101:147–57.

  140. Taafe DR, Sipila S, Cheng S, et al. The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clin Physiol Funct Imaging. 2005;25:297–304.

  141. Skelton DA, Phillips SK, Bruce SA, et al. Hormone replacement therapy increases isometric strength of adductor pollicis in post-menopausal women. Clin Sci. 1999;96:357–64.

  142. Onambele-Pearson GL. HRT affects skeletal muscle contractile characteristics: a definitive answer? J Appl Physiol. 2009;107:4–5.

  143. Dieli-Conwright CM, Spektor TM, Rice JC, et al. Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women. J Appl Physiol. 2009;107:853–8.

  144. Dieli-Conwright CM, Spektor TM, Rice JC, et al. Influence of hormone replacement therapy on eccentric exercise induced mygenic gene expression in postmenopausal women. J Appl Physiol. 2009;107:1381–8.

  145. Pollanen E, Ronkainen PHA, Hortanainen M, et al. Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle. Growth Horm IGF Res. 2010;20:372–9.

  146. Kamanga-Sollo E, White ME, Hathaway MR, et al. Roles of IGF-1 and the estrogen, androgen and IGF-1 receptors ikn estradiol-17ÎČ- and trenbolone acetate-stimulated proliferation of cultured bovine satellite cells. Dom Animal Endocrinol. 2008;35:88–97.

  147. Brown M. Skeletal muscle and bone: effect of sex steroids and aging. Adv Physiol Ed. 2008;32:120–6.

  148. Greising SM, Baltgalvis KA, Lowe DA, et al. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2009;64:1071–81.

  149. Tiidus PM. Influence of estrogen on Muscle Plasticity. Brazil J Boimet. 2011;5 (In Press).

  150. Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2009;64:1071–81.

  151. Meeuwsen IB, Samson MM, Verhaar HJ. Evaluation of the applicability of HRT as a preservative of muscle strength in women. Maturitas. 2000;36:49–61.

  152. Phillips SK, Rook KM, Siddle NC, Bruce SA, Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clin Sci (Lond) 1993;84:95–8.

  153. Sipila S, Poutamo J. Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. Scand J Med Sci Sports. 2003;13:19–25.

  154. Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci 64: 1071–1081, 2009.

  155. Pollanen E, Sipila S, Alen M, Ronkainen PH, Ankarberg-Lindgren C, Puolakka J, Suominen H, Hamalainen E, Turpeinen U, Konttinen YT, Kovanen V. Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and postmenopausal women. Aging Cell 10: 650–660, 2011.

  156. Tiidus PM. Benefits of Estrogen Replacement for Skeletal Muscle Mass and Function in Post-Menopausal Females: Evidence from Human and Animal Studies. The Eurasian Journal of Medicine. 2011;43(2):109-114. doi:10.5152/eajm.2011.24.

  157. Tiidus PM, Lowe DA, Brown M. Estrogen replacement and skeletal muscle: mechanisms and population health. Journal of Applied Physiology. 2013;115(5):569-578. doi:10.1152/japplphysiol.00629.2013.

  158. Dionne IJ, Kinaman KA, Poehlman ET. Sarcopenia and muscle function during menopause and hormone-replacement therapy. The journal of nutrition, health & aging. 2000; 4(3):156-61.

  159. SipilÀ S, Taaffe DR, Cheng S, Puolakka J, Toivanen J, Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clinical science (London, England : 1979). 2001; 101(2):147-57.

  160. Kenny AM, Dawson L, Kleppinger A, Iannuzzi-Sucich M, Judge JO. Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen-replacement therapy. The journals of gerontology. Series A, Biological sciences and medical sciences. 2003; 58(5):M436-40.

  161. SipilÀ S. Body composition and muscle performance during menopause and hormone replacement therapy. Journal of endocrinological investigation. 2003; 26(9):893-901.

  162. Lowe DA, Baltgalvis KA, Greising SM. Mechanisms behind Estrogens’ Beneficial Effect on Muscle Strength in Females. Exercise and sport sciences reviews. 2010;38(2):61-67. doi:10.1097/JES.0b013e3181d496bc.

  163. Wend K, Wend P, Krum SA. Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging. Frontiers in Endocrinology. 2012;3:19. doi:10.3389/fendo.2012.00019.

  164. Frizziero A, Vittadini F, Gasparre G, Masiero S. Impact of oestrogen deficiency and aging on tendon: concise review. Muscles, Ligaments and Tendons Journal. 2014;4(3):324-328.

  165. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The Role of Androgens and Estrogens on Healthy Aging and Longevity. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2012;67(11):1140-1152. doi:10.1093/gerona/gls068.

  166. Komulainen J, Koskinen S, Kalliokoski R, et al. Gender differences in skeletal muscle fibre damage after eccentrically biased downhill running in rats. Acta Physiol Scand. 1999;165:57–63.

  167. Amelink GL, Koot RW, Erich WB, et al. Sex-linked variation in creatine kinase release, and its dependence on oestradiol, can be demonstrated in an in vitro rat skeletal muscle preparation. Acta Physiol Scand. 1990;138:115–34.

  168. Tiidus PM. Estrogen and gender effects on post-exercise muscle damage, inflammation and oxidative stress. Can J Appl Physiol. 2000;25:274–87.

  169. Bar PR, Amelink GL, Oldenburg B, et al. Prevention of exercise-induced muscle membrane damage by oestradiol. Life Sci. 1988;42:2677–81.

  170. Tiidus PM. Influence of estrogen and gender on muscle damage, inflammation and repair. Exerc Sport Sci Rev. 2003;31:40–4.

  171. Rasgon NL, Altshuler LL, Fairbanks LA. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. The Journal of clinical psychiatry. 2002; 63 Suppl 7:45-8.

  172. Stephens C, Pachana NA, Bristow V. The effect of hormone replacement therapy on mood and everyday memory in younger mid-life women. Psychology, health & medicine. 2006; 11(4):461-9.

  173. Sichel DA., Cohen LS., Robertson LM., Ruttenberg A., Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38:814–818.

  174. Gregoire AJ., Kumar R., Everitt B., Henderson AF., Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930–933.

  175. Gregoire AJ., Kumar R., Everitt B., Henderson AF., Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:930–933.

  176. Schmidt, Rubinow P., DR Sex hormones and mood in the perimenopause. Ann N Y Acad Sci. 2009;1179:70–85.

  177. Schneider L., Small G., Hamilton S., Bystritsky A., Nemeroff C., Meyers B. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry. 1997;5:97–106.

  178. Soares C., Poitras J., Prouty J., Alexander A., Shifren J., Cohen L. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry. 2003;64:473–479.

  179. Schneider L., Small G., Clary C. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry. 2001;9:393–399.

  180. Amsterdam J., Garcia-Espana F., Fawcett J., et al Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999;55:11–17.

  181. Schmidt P., Nieman L., Danaceau M., et al Estrogen replacement in per imenopa use-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414–420.

  182. Albertazzi P, Natale V, Barbolini C, Teglio L, Di Micco R. The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: a pilot study. Maturitas. 2000 Oct 31;36(3):223–9.

  183. Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology. 2005 May;30(4):309–15.

  184. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000 Aug;183(2):414–20.

  185. Onalan G, Onalan R, Selam B, Akar M, Gunenc Z, Topcuoglu A. Mood scores in relation to hormone replacement therapies during menopause: a prospective randomized trial. Tohoku J Exp Med. 2005 Nov;207(3):223–31.

  186. Karsidag C, Karsidag A, Buyukbayrak E, kars B, Pirimoglu M, Unal O, Turan C. Comparison of effects of two different hormone therapies on mood and symptomatic postmenopausal women. Arch Neuropsychiatry. 2012;49:39–43.

  187. Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology. 1997; 22(7):549-58.

  188. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15:797–817.

  189. Zweifel JE, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189–212.

  190. Wharton W, Gleason CE, Olson SRMS, Carlsson CM, Asthana S. Neurobiological Underpinnings of the Estrogen – Mood Relationship. Current psychiatry reviews. 2012;8(3):247-256. doi:10.2174/157340012800792957

  191. Brincat M, Versi E, Moniz CF, Magos A, de Trafford J, Studd JW. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987;70:123–7.

  192. Punnonen R. Effect of castration and peroral estrogen therapy on the skin. Acta Obstet Gynecol Scand Suppl. 1972;21:3–44.

  193. Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol. 1994;170:642–9.

  194. Son ED, Lee JY, Lee S, Kim MS, Lee BG, Chang IS, et al. Topical application of 17beta-estradiol increases extracellular matrix protein synthesis by stimulating tgf-Beta signaling in aged human skin in vivo. J Invest Dermatol. 2005;124:1149–61. doi: 10.1111/j.0022-202X.2005.23736.x.

  195. Maheux R, Naud F, Rioux M, Grenier R, Lemay A, Guy J, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol. 1994;170:642–9.

  196. Sauerbronn AV, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynaecol Obstet. 2000;68:35–41. doi: 10.1016/S0020-7292(99)00166-6.

  197. Savvas M, Bishop J, Laurent G, Watson N, Studd J. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol. 1993;100:154–6. doi: 10.1111/j.1471-0528.1993.tb15212.x.

  198. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol. 1996;35:669–74. doi: 10.1111/j.1365-4362.1996.tb03701.x.

  199. Varila E, Rantala I, Oikarinen A, Risteli J, Reunala T, Oksanen H, et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol. 1995;102:985–9. doi: 10.1111/j.1471-0528.1995.tb10906.x.

  200. Brincat M, Moniz CF, Studd JWW, Darby AJ, Magos A, Cooper D. Sex hormones and skin collagen content in postmenopausal women. Br Med J (Clin Res Ed) 1983;287:1337–8.

  201. Brincat M, Moniz CJ, Studd JWW, et al. Longterm effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985;92:256–9.

  202. Brincat M, Versi E, Moniz CF, Magos A, de Trafford J, Studd JW. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987;70:123–7.

  203. Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery J. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstet Gynecol 1987;70:840–5.

  204. Castelo-Branco C, Duran M, Gonzalez-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992;15:113–19.

  205. Savvas M, Bishop J, Laurent G, Watson N, Studd J. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993;100:154–6.

  206. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of skin aging with topical estrogens. Int J Dermatol 1996;35:669–74.

  207. Varila E, Rantala I, Oikarinen A, et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995;102:985–9.

  208. Sauerbronn AVD, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynaecol Obstet 2000;68:35–41.

  209. Haapasaari K-M, Raudaskoski T, Kallioinen M, et al. Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women. Maturitas 1997;27:153–6.

  210. Sauerbronn AVD, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. International Journal of Gynecology and Obstetrics. 2000;68(1):35–41.

  211. Calleja-Agius J, Brincat M, Borg M. Skin connective tissue and ageing. Best Practice & Research Clinical Obstetrics & Gynaecology. 2013;27:727–740.

  212. Wolff EF, Narayan D, Taylor HS. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril. 2005;84:285–8. doi: 10.1016/j.fertnstert.2004.12.062.

  213. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause : implications for treatment. American journal of clinical dermatology. 2003; 4(6):371-8.

  214. Shah MG, Maibach HI. Estrogen and skin. An overview. American journal of clinical dermatology. 2001; 2(3):143-50.

  215. Pierard-Franchimont C, Letawe C, Goffin V, Pierard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995;22:151–4.

  216. Sator PG, Schmidt JB, Sator MO, Huber JC, Honigsmann H. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001;39:43–55.

  217. Schmidt JB, Binder M, Macheiner W, Kainz C, Gitsch G, Bieglmayer C. Treatment of skin ageing symptoms in perimenopausal females with estrogen compound. A pilot study. Maturitas 1994;20:25–30.

  218. Guinot C, Malvy D, Ambroisine L, et al. Effect of hormonal replacement therapy on skin biophysical properties of menopausal women. Skin Research and Technology. 2005;11(4):201–204.

  219. PiĂ©rard-Franchimont C, Letawe C, Goffin V, PiĂ©rard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas. 1995;22(2):151–154.

  220. Paquet F, PiĂ©rard-Franchimont C, Fumal I, Goffin V, Paye M, PiĂ©rard GE. Sensitive skin at menopause; dew point and electrometric properties of the stratum corneum. Maturitas. 1998;28(3):221–227.

  221. Calleja-Agius J, Brincat M, Borg M. Skin connective tissue and ageing. Best practice & research. Clinical obstetrics & gynaecology. 2013; 27(5):727-40.

  222. Punnonen R. Effect of castration and peroral estrogen therapy on the skin. Acta Obstet Gynecol Scand Suppl. 1972;21:3–44.

  223. Urano R, Sakabe K, Seiki K, et al. Female sex hormone stimulates cultured human keratinocyte proliferation and its RNA- and protein-synthetic activities. J Dermatol Sci. 1995;9:176–84.

  224. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol. 2004;123:319–28.

  225. Verdier-Sevrain S, Yaar M, Cantatore J, et al. Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism. Faseb J. 2004;18:1252–4.

  226. Thornton MJ, Taylor AH, Mulligan K, et al. Estrogen receptor beta (ERÎČ) is the predominant estrogen receptor in human scalp. Exp Dermatol. 2003;12:181–90.

  227. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol. 2004;123:319–28.

  228. Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clinical Interventions in Aging. 2007;2(3):283-297.

  229. Rittié L, Kang S, Voorhees JJ, Fisher GJ. Induction of collagen by estradiol: difference between sun-protected and photodamaged human skin in vivo. Archives of dermatology. 2008; 144(9):1129-40.

  230. Röck K, Meusch M, Fuchs N, et al. Estradiol Protects Dermal Hyaluronan/Versican Matrix during Photoaging by Release of Epidermal Growth Factor from Keratinocytes. The Journal of Biological Chemistry. 2012;287(24):20056-20069. doi:10.1074/jbc.M112.353151

  231. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. American Journal of Clinical Dermatology. 2003;4(6):371–378.

  232. Verdier-SĂ©vrain S, BontĂ© F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. Experimental Dermatology. 2006;15(2):83–94.

  233. Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. International Journal of Cosmetic Science. 2008;30(2):87–95.

  234. Castelo-Branco C, Gigueras F, Martínez de Osaba MJ, Vanrell JA. Facial wrinkling in postmenopausal women. Effects of smoking status and hormone replacement therapy. Maturitas. 1998;29(1):75–86.

  235. PiĂ©rard-Franchimont C, Cornil F, Dehavay J, Deleixhe-Mauhin F, Letot B, PiĂ©rard GE. Climacteric skin ageing of the face—a prospective longitudinal comparative trial on the effect of oral hormone replacement therapy. Maturitas. 1999;32(2):87–93.

  236. Quatresooz P, PiĂ©rard G. Downgrading skin climacteric aging by hormone replacement therapy. Expert Review of Dermatology. 2007;2(4):373–376.

  237. Pierard GE, Hermanns-LĂȘ T, Paquet P, PiĂ©rard-Franchimont C. Skin viscoelasticity during hormone replacement therapy for climacteric ageing. International Journal of Cosmetic Science. 2013.

  238. Pierard GE, Vanderplaetsen S, PiĂ©rard-Franchimont C. Comparative effect of hormone replacement therapy on bone mass density and skin tensile properties. Maturitas. 2001;40(3):221–227.

  239. Hermanns-LĂȘ T, Uhoda I, Smitz S, PiĂ©rard GE. Skin tensile properties revisited during ageing. Where now, where next? Journal of Cosmetic Dermatology. 2004;3:35–40.

  240. Henry F, Pierard-Franchimont C, Cauwenbergh G, Pierard GE. Age-related changes in facial skin contours and rheology. J Am Geriatr Soc 1997;45:220–2.

  241. Pierard GE, Letawe C, Dowlati A, PierardFranchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995;43:662–5.

  242. Sator PG, Schmidt JB, Sator MO, Huber JC, Honigsmann H. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001;39:43–55.

  243. Sumino H, Ichikawa S, Abe M, Endo Y, Ishikawa O, Kurabayashi M. Effects of aging, menopause and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004;52:945–9.

  244. Youn CS, Kwon OS, Won CH, et al. Effect of pregnancy and menopause on facial wrinkling in women. Acta Derm Venereol 2003;83:419–24.

  245. Pierard-Franchimont C, Cornil F, Dehavau J, Deleixhe-Mauhin F, Letot B, Pierard GE. Climacteric skin ageing of the face – a prospective longitudinal comparative trial on the effect of oral hormone replacement therapy. Maturitas 1999;32:87–93.

  246. Haskell SG, Richardson ED, Horwitz RI. The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. Journal of clinical epidemiology. 1997; 50(11):1249-64.

  247. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women. The Cochrane database of systematic reviews. 2002.

  248. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA. 1998;279:688–695.

  249. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489–1499.

  250. Brett K, Chong Y. Hormone Replacement Therapy: Knowledge and Use in the United States. Hyattsville, Maryland: National Center for Health Statistics; 2001.

  251. Miller BL, Cummings JL. The Frontal Lobes: Functions and Disorders. New York: Guilford Press; 1999. (trans.)

  252. Ramage A, Bayles K, Helm-Estabrooks N, Cruz R. Frequency of perseveration in normal subjects. Brain Lang. 1999;66:329–340.

  253. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology. 2001;26:577–590.

  254. Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13:411–422.

  255. Wegesin DJ, Stern Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:301–328.

  256. Albert MS, Kaplin E. Organic Implications of neuropsychological deficits in the elderly. In: Poon JLFLW, Cermak LS, Arenberg D, Thompson W, editors. New Directions in Memory and Aging: Proceedings of the George A. Talland Memorial Conference. Hillsdale, NJ: Erlbaum; 1980. pp. 403–432.

  257. Craik FIM, Jennings JM. Human Memory. Hillsdale, NJ: Erlbaum Associates; 1992. (trans.)

  258. Dempster FN. The rise and fall of the inhibitory mechanism: toward a unified theory of cognitive development and aging. Dev Rev. 1992;12:45–75.

  259. Moscovitch MW, Winocur G. The neuropsychology of memory and aging. In: Craik TASFIM, editor. The Handbook of Aging and Cognition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.; 1992. pp. 315–372.

  260. Stuss DT, Craik FI, Sayer L, Franchi D, Alexander MP. Comparison of older people and patients with frontal lesions: evidence from world list learning. Psychol Aging. 1996;11:387–395.

  261. West RL. An application of prefrontal cortex function theory to cognitive aging. Psychol Bull. 1996;120:272–292.

  262. Berman KF, Schmidt PJ, Rubinow DR, Danaceau MA, Van Horn JD, Esposito G, Ostrem JL, Weinberger DR. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA. 1997;94:8836–8841.

  263. D’Esposito M, Postle BR, Ballard D, Lease J. Maintenance versus manipulation of information held in working memory: an event-related fMRI study. Brain Cogn. 1999;41:66–86.

  264. Cabeza R, Nyberg L. Neural bases of learning and memory: functional neuroimaging evidence. Curr Opin Neurol. 2000;13:415–421.

  265. Manoach DS, Greve DN, Lindgren KA, Dale AM. Identifying regional activity associated with temporally separated components of working memory using event-related functional MRI. Neuroimage. 2003;20:1670–1684.

  266. Veltman DJ, Rombouts SA, Dolan RJ. Maintenance versus manipulation in verbal working memory revisited: an fMRI study. Neuroimage. 2003;18:247–256.

  267. Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy. Horm Behav. 2000;38:262–276.

  268. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology. 2001;26:577–590.

  269. Grigorova M, Sherwin BB, Tulandi T. Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women. Psychoneuroendocrinology. 2006;31:935–947.

  270. Erickson KI, Colcombe SJ, Elavsky S, McAuley E, Korol DL, Scalf PE, Kramer AF. Interactive effects of fitness and hormone treatment on brain health in postmenopausal women. Neurobiol Aging. 2007;28:179–185.

  271. Wegesin DJ, Stern Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:301–328.

  272. Erickson KI, Colcombe SJ, Elavsky S, McAuley E, Korol DL, Scalf PE, Kramer AF. Interactive effects of fitness and hormone treatment on brain health in postmenopausal women. Neurobiol Aging. 2007;28:179–185.

  273. Wegesin DJ, Stern Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:301–328.

  274. Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA. Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause. 2006;13:411–422.

  275. Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Skudlarski P, Mencl WE, Constable RT, Naftolin F, Palter SF, Marchione KE, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 1999;281:1197–1202.

  276. Craig MC, Fletcher PC, Daly EM, Rymer J, Cutter WJ, Brammer M, Giampietro V, Wickham H, Maki PM, Murphy DG. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology. 2007;32:1116–1127.

  277. Craig MC, Fletcher PC, Daly EM, Rymer J, Brammer M, Giampietro V, Maki PM, Murphy DG. Reversibility of the effects of acute ovarian hormone suppression on verbal memory and prefrontal function in pre-menopausal women. Psychoneuroendocrinology. 2008a.

  278. Craig MC, Fletcher PC, Daly EM, Rymer J, Brammer M, Giampietro V, Stahl D, Maki PM, Murphy DG. The interactive effect of the cholinergic system and acute ovarian suppression on the brain: An fMRI study. Horm Behav. 2008b.

  279. Grigorova M, Sherwin BB. No differences in performance on test of working memory and executive functioning between healthy elderly postmenopausal women using or not using hormone therapy. Climacteric. 2006;9:181–194.

  280. Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy. Horm Behav. 2000;38:262–276.

  281. Wegesin DJ, Stern Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14:301–328.

  282. Maki PM. Estrogen effects on the hippocampus and frontal lobes. Int. J. Fertil. Womens Med. 50, 67–71 (2005).

  283. Duff SJ, Hampson E. A beneficial effect of estrogen on working memory in ostmenopausal women taking hormone replacement therapy. Horm. Behav. 38, 262–276 (2000).

  284. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology. 26, 577–590 (2001).

  285. Petrides M, Alivisatos B, Meyer E. Functional activation of the human frontal cortex during the performance of verbal working memory tasks. Proc. Natl Acad. Aci. USA 90, 878–882 (1993).

  286. Badre D, Wagner AD. Left ventrolateral prefrontal cortex and the cognitive control of memory. Neuropsychologia 45(13), 2883–2901 (2007).

  287. Grady CL, Craik FIM. Changes in memory processing with age. Curr. Opin. Neurobiol. 10, 224–231 (2000).

  288. Jakob RL, Goldman-Rakic PS. 5-hydroxytryptamine 2a serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl Acad. Sci. USA 95, 735–740 (1998).

  289. Gotham AM, Brown RG, Marsden CP. ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 111, 299–321 (1988).

  290. Williams G, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572–575 (1995).

  291. Kritzer MF, Kohama SG. Ovarian hormones influence the morphology, distribution, and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult rhesus monkeys. J. Comp. Neurol. 395, 1–17 (1998).

  292. Kritzer MF, Kohama SG. Ovarian hormones differentially influence immuno-reactivity for dopamine ÎČ-hydroxylase, choline acetyltransferase, and serotonin in the dorsolateral prefrontal cortex of adult rhesus monkeys. J. Comp. Neurol. 409, 438–451 (1999).

  293. Frick KM. Estrogens and age-related memory decline in rodents: what have we learned and where do we go from here? Horm. Behav. 2009;55:2–23.

  294. Joffe H, Hall J, Gruber S, Sarmiento I. Estrogen therapy selectively enhances pre-frontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently post-menopausal women. Menopause. 2006;13:411–422.

  295. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485–495.

  296. Viscoli C, Brass L, Kernan W, Sarrel P. Estrogen therapy and risk of cognitive decline: results from the Women’s Estrogen for Stroke Trial (WEST) Am J Obstet Gynecol. 2005;192:387–393.

  297. Wolf OT, Kudielka BM, Hellhammer DH, Törber S, McEwen BS, Kirschbaum C. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrinology. 1999;24:727–741.

  298. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002;288:2170–2172.

  299. Sherwin BB. Estrogen and cognitive functioning in women: lessons we have learned. Behav Neurosci. 2012;126:123–127.

  300. Singh M, Simpkins JW, Bimonte-Nelson HA, Brinton RD. Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer’s disease. Brain Res. 2013;1514:1–2.

  301. Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause. 2013;20:695–709.

  302. Sherwin BB. Estrogen and cognitive functioning in women. Endocrine reviews. 2003; 24(2):133-51.

  303. Ryan J, CarriĂšre I, Scali J. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology. 2009; 73(21):1729-37.

  304. McEwen B. The molecular and neuroanatomical basis for estrogen effects in the central nervous system. J Clin Endocrinol Metab. . 1999;84:1790-1797.

  305. Cholerton B, Gleason C, Asthana S. Estrogen and Alzheimer’s disease: the story so far. Drugs Aging. . 2002;19:405-427.

  306. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. . 1998;279:688-695.

  307. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. . 2002;288:321-333.

  308. Whitmer RA, Haan MN, Miller JW, Yaffe K. Hormone replacement therapy and cognitive performance: the role of homocysteine. J Gerontol Med Sci. . 2003;58A:000-000.

  309. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep. 1988; 11(6):556-61.

  310. Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? American journal of obstetrics and gynecology. 1998; 178(5):1002-9.

  311. Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2012;19:610–615.

  312. Danckers L, Blumel JE, Witis S, et al. Personal and professional use of menopausal hormone therapy among gynecologists: a multinational study (REDLINC VII) Maturitas. 2016;87:67–71.

  313. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.

  314. Keefe DL, Watson R, Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. Menopause (New York, N.Y.). 1999; 6(3):196-200.

  315. Cistulli PA, Barnes DJ, Grunstein RR, Sullivan CE. Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax. 1994;49(7):699-702.

  316. Wesström J, Ulfberg J, Nilsson S. Sleep apnea and hormone replacement therapy: a pilot study and a literature review. Acta obstetricia et gynecologica Scandinavica. 2005; 84(1):54-7.

  317. Saletu-Zyhlarz G, Anderer P, Gruber G. Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone. Journal of sleep research. 2003; 12(3):239-54.

  318. Manber R, Kuo TF, Cataldo N, Colrain IM. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep. 2003; 26(2):163-8.

  319. Young T. Menopause, hormone replacement therapy, and sleep-disordered breathing: are we ready for the heat? American journal of respiratory and critical care medicine. 2001; 163(3 Pt 1):597-8.

  320. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause (New York, N.Y.). ; 8(1):10-6.

  321. Shahar E, Redline S, Young T. Hormone replacement therapy and sleep-disordered breathing. American journal of respiratory and critical care medicine. 2003; 167(9):1186-92.

  322. Scharf MB, McDannold MD, Stover R, Zaretsky N, Berkowitz DV. Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study. Clinical therapeutics. ; 19(2):304-11.

  323. Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, et al. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril. 1999;71:873–880.

  324. Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100:1209–1218.

  325. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ. 2008;337:a1190.

  326. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414–420.

  327. Santoro N, Epperson CN, Mathews SB., 2 Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44:497–515.

  328. Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, et al. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertil Steril. 1999;71:873–880.

  329. Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. J Womens Health (Larchmt) 2014;23:18–28.]

  330. Polo-Kantola P, Erkkola R, Irjala K, Pullinen S, Virtanen I, Polo O. Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women. Fertility and sterility. 1999; 71(5):873-80.

  331. Antonijevic IA, Stalla GK, Steiger A. Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women. American journal of obstetrics and gynecology. 2000; 182(2):277-82.

  332. Huffman KM, Slentz CA, Johnson JL, et al. Impact of Hormone Replacement Therapy on Exercise Training-Induced Improvements in Insulin Action in Sedentary Overweight Adults. Metabolism: clinical and experimental. 2008;57(7):888-895. doi:10.1016/j.metabol.2008.01.034.

  333. Taaffe DR, SipilÀ S, Cheng S, Puolakka J, Toivanen J, Suominen H. The effect of hormone replacement therapy and/or exercise on skeletal muscle attenuation in postmenopausal women: a yearlong intervention. Clinical physiology and functional imaging. 2005; 25(5):297-304.

  334. Sipila S, Taffe DR, Cheng S, et al. Effects of hormone replacement therapy and high impact physical exercise on skeletal muscle in post-menopausal women: a randomized control trial. Clin Sci. 2001;101:147–57.

  335. Kohrt WM, Van Pelt RE, Gozansky WS. Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism. Journal of endocrinological investigation. 2003; 26(9):902-10.

  336. Skelton DA, Phillips SK, Bruce SA, et al. Hormone replacement therapy increases isometric strength of adductor pollicis in post-menopausal women. Clin Sci. 1999;96:357–64.

  337. Skelton DA, Phillips SK, Bruce SA, et al. Hormone replacement therapy increases isometric strength of adductor pollicis in post-menopausal women. Clin Sci. 1999;96:357–64.

  338. Kenny AM, Dawson I, Kleppinger A, et al. Prevalence of sarcopenia and predictors of skeletal muscle mass in nonobese women who are long-term users of estrogen replacement therapy. J Gerontol A Med Sci. 2003;58:436–40.

  339. Brown M. Skeletal muscle and bone: effect of sex steroids and aging. Adv Physiol Ed. 2008;32:120–6.

  340. SipilÀ S. Body composition and muscle performance during menopause and hormone replacement therapy. Journal of endocrinological investigation. 2003; 26(9):893-901.

  341. McCully KS, Jackson S. Hormone replacement therapy and the bladder. The journal of the British Menopause Society. 2004; 10(1):30-2.

  342. Raz R. Hormone replacement therapy or prophylaxis in postmenopausal women with recurrent urinary tract infection. The Journal of infectious diseases. 2001; 183 Suppl 1:S74-6.

  343. Raz, R. Role of estriol therapy for women with recurrent urinary tract infections: Advantages and disadvantages. Infect. Dis. Clin. Pract. 1999; 8: 64–66.

  344. Iosif, C.S and Bekassy, Z. Prevalence of genito-urinary symptoms in the last menopause. Acta. Obstet. Gynecol. Scand. 1984; 63: 257–260.

  345. Brocklehurst, J.C, Dillane, J.B, Griffiths, L et al. The prevalence and symptomatology of urinary infection in an aged population. Gerontology. 1968; 10: 242–253.

  346. Raz, R and Stamm, W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N. Engl. J. Med. 1993; 329: 753–756.

  347. Rozeberg, A. Pastijn, R. Gevers, D. Murillo. Estrogen therapy in older patients with recurrent urinary tract infections: a review. Int J Fertil, 49 (2004), pp. 71-74.

  348. Mattson, L.A and Cullberg, G. Vaginal absorption of two estriol preparations: a comparative study in postmenopausal women. Acta. Obstet. Gynecol. Scand. 1983; 62: 393–396.

  349. Raz, W.E. Stamm. A controlled trial of intra-vaginal oestriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med, 329 (1993), pp. 753-756.

  350. Luthje, H. Brauner, N. L. Ramos, A. Ovregaard, R. Glaser, A. L. Hirschberg, P. Aspenstrom, A. Brauner. Estrogen Supports Urothelial Defense Mechanisms. Science Translational Medicine, 2013; 5 (190): 190ra80 DOI: 10.1126/scitranslmed.3005574.

  351. C. Eriksen. A randomised, open, parallel group study on the preventative effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynaecol, 180 (1999), pp. 1072-1079.

  352. L. Kirkengen, P. Andersen, E. GjersĂže, G.R. Johannessen, N. Johnsen, E. Bodd. Oestriol in the prophylactic treatment of recurrent UTI in postmenopausal women Scand J Prim Health Care, 10 (1992), pp. 139-142.

  353. Jármy-di Bella ZI, Girão MJ, Di Bella V, et al. Hormonal influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas. 2007;56:297–302.

  354. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women [review] Cochrane Database Syst Rev. 2003;2:CD001405.

  355. Perrotta C, Aznar M, Mejia R, et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;2:CD005131.

  356. Theofrastous JP, Addison WA, Timmons MC. Voiding function following prolapse surgery. Impact of estrogen replacement. J Reprod Med. 1996;41:881–4.

  357. Mancini F, Persico N, Genazzani AD, et al. Effects of hormone replacement therapy on plasma viscosity and Doppler variations in postmenopausal non-smokers and heavy smokers. Gynecol Endocrinol. 2005;20:221–6.

  358. Persico N, Mancini F, Artini PG, et al. Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients. Gynecol Endocrinol. 2004;19:274–81.

  359. Hodis HN. Assessing benefits and risks of hormone therapy in 2008: New evidence, especially with regard to the heart. Cleve Clin J Med. 2008;75(S4):S3–12.

  360. Lukes A. Evolving issues in the clinical and managed care settings on the management of menopause following the Women’s Health Initiative. J Manag Care Pharm. 2008;14(Suppl):7–13.

  361. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–941.

  362. Rosano GM, Vitale C, Fini M. Cardiovascular aspects of menopausal hormone replacement therapy. Climacteric. 2009;12 (Suppl 1):41–46.

  363. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29:289–295.

  364. Babiker FA, De Windt LJ, van Eickels M, et al. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res. 2002;53:709–719.

  365. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenom. 2004;4:19–28.

  366. Ruehlmann DO, Mann GE. Rapid nongenomic vasodilator actions of oestrogens and sex steroids. Curr Med Chem. 2000;7:533–541.

  367. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol. 2009;308:32–38.

  368. Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol. 2009;297:H1806–H1813. A recent study showing that activation of the newly discovered estrogen receptor, GPER, improves cardiac function and reduces infarct size.

  369. Lagranha CJ, Deschamps A, Aponte A, et al. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res. 2010;106:1681–1691.

  370. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29:289–295.

  371. Zhang QG, Raz L, Wang R, et al. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci. 2009;29:13823–13836.

  372. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation. 2009;120:245–254.

  373. Donaldson C, Eder S, Baker C, et al. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res. 2009;104:265–275.

  374. Liu CJ, Lo JF, Kuo CH, et al. Akt mediates 17beta-estradiol and/or estrogen receptor-alpha inhibition of LPS-induced tumor necresis factor-alpha expression and myocardial cell apoptosis by suppressing the JNK1/2-NFkappaB pathway. J Cell Mol Med. 2009;13:3655–3667.

  375. Xing D, Nozell S, Chen YF, et al. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29:289–295.

  376. Reckelhoff JF. Cardiovascular disease, estrogen deficiency, and inflammatory cytokines. Hypertension. 2006;48:372–373.

  377. Erwin GS, Crisostomo PR, Wang Y, et al. Estradiol-treated mesenchymal stem cells improve myocardial recovery after ischemia. J Surg Res. 2009;152:319–324.

  378. Baruscotti I, Barchiesi F, Jackson EK, et al. Estradiol stimulates capillary formation by human endothelial progenitor cells: role of estrogen receptor-alpha/beta, heme oxygenase 1, and tyrosine kinase. Hypertension. 2010;56:397–404.

  379. Bolego C, Rossoni G, Fadini GP, et al. Selective estrogen receptor-alpha agonist provides widespread heart and vascular protection with enhanced endothelial progenitor cell mobilization in the absence of uterotrophic action. FASEB J. 2010;24:2262–2272. New mechanisms that may be responsible for the cardioprotective action of estrogen

  380. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769–1775.

  381. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–941.

  382. Retrieved from https://www.medicalnewstoday.com/articles/251305.php.

  383. Sullivan JMZwaag  RVHughes  JP  et al.  Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women.  Arch Intern Med. 1990;1502557- 2562.

  384. Falkeborn MPersson  IAdami  HO  et al.  The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement.  Br J Obstet Gynaecol. 1992;99821- 828.

  385. Psaty BMHeckbert  SRAtkins  D  et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women.  Arch Intern Med. 1994;1541333- 1339.

  386. Grady DRubin  SMPetitti  DB  et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women.  Ann Intern Med. 1992;1171016- 1037.

  387. Espeland MAApplegate  WFurberg  CDLefkowitz  DRice  LHunningshake  D Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women.  Am J Epidemiol. 1995;1421011- 1019.

  388. Hough JLZilversmit  DB Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits.  1986;657- 63.

  389. Haarbo JLeth-Espensen  PStender  SChristiansen  C Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits.  J Clin Invest. 1991;871274- 1279.

  390. Adams MRKaplan  JRManuck  SB  et al.  Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone.  1990;101051- 1057.

  391. Adams MRRegister  TCGolden  DLWagner  JDWilliams  JK Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis.  Arterioscler Thromb Vasc Biol. 1997;17217- 221.

  392. Williams JKAnthony  MSHonorĂ©  EK  et al.  Regression of atherosclerosis in female monkeys.  Arterioscler Thromb Vasc Biol. 1995;15827- 836.

  393. ullivan JMZwaag  RVHughes  JP  et al.  Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women.  Arch Intern Med. 1990;1502557- 2562.

  394. Espeland MAApplegate  WFurberg  CDLefkowitz  DRice  LHunningshake  D Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women.  Am J Epidemiol. 1995;1421011- 1019.

  395. Wakatsuki AIkenoue  NSagara  Y Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women.  1998;28229- 234.

  396. Reis SEGloth  STBlumenthal  RS  et al.  Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women.  1994;8952- 60.

  397. Roque MHeras  MRoig  E  et al.  Short-term effects of transdermal estrogen therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms.  J Am Coll Cardiol. 1998;31139- 143.

  398. Lau TKChung  TKHaines  CJ A preliminary study on the effect of hormone replacement therapy on peripheral flow velocity in postmenopausal women.  1997;2653- 56.

  399. Sorensen KEDorup  IHermann  APMosekilde  L Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function.  1998;971234- 1238.

  400. Bush DEJones  CEBass  KMWalters  GKBruza  JMOuyang  P Estrogen replacement reverses endothelial dysfunction in postmenopausal women.  Am J Med. 1998;104552- 558.

  401. Sullivan JMShala  BAMiller  LALerner  JLMcBrayer  JD Progestin enhances vasoconstrictor response in postmenopausal women receiving estrogen replacement therapy.  1995;2193- 199.

  402. Gerhard MWalsh  BWTawakol  A  et al.  Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women.  1998;981158- 1163.

  403. Rosano GMLeonardo  FPanina  G  et al.  Comparative effect of continuous combined hormone replacement therapy with either conjugated equine oestrogens plus medroxyprogesterone acetate or 17ÎČ-oestradiol plus norethisterone acetate on brachial artery blood flow [abstract].  Eur Heart J. 1998;19(suppl)681.

  404. Walsh BWSchiff  IRosner  BGreenberg  LRavnikar  VSacks  FM Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.  N Engl J Med. 1991;3251196- 1204.

  405. McManus JMcEneny  JThompson  WYoung  IS The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.  1997;13573- 81.

  406. Pornel B Efficacy and safety of Menorest in two positive-controlled studies.  Eur J Obstet Gynecol Reprod Biol. 1996;64(suppl 1)S35- S37.

  407. Egeland GM, Kuller LH, Matthews KA, Kelsey SF, Cauley J, Guzick D. Hormone replacement therapy and lipoprotein changes during early menopause. Obstetrics and gynecology. 1990; 76(5 Pt 1):776-82.

  408. Paganini-Hill A, Dworsky R, Krauss RM. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. American journal of obstetrics and gynecology. 1996; 174(3):897-902.

  409. Fahraeus L. The effects of estradiol on blood lipids and lipoproteins in postmenopausal women. Obstetrics and gynecology. 1988; 72(5 Suppl):18S-22S.

  410. Saranyaratana W, Sakondhavat C, Silaruks S, Soontrapa S, Kaewrudee S. Effect of hormone therapy on lipid profile in menopausal women. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2006; 89 Suppl 4:S37-41.

  411. Granfone A, Campos H, McNamara JR. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism: clinical and experimental. 1992; 41(11):1193-8.

  412. Campagnoli C, Belforte P, Di Sario MM, Lesca L. Lipid profile during hormone replacement therapy: effect of different progestins? Zentralblatt fur Gynakologie. 1997; 119 Suppl 2:1-6.

  413. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861–1867.

  414. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47–63.

  415. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med. 1991;325:756–762.

  416. Jeon GH, Cho HJ, Chun S, Ji YI, Jeong CH, Suh MH, et al. The occurrence of glaucoma and association with serum estradiol level in postmenopausal women. J Korean Soc Menopause. 2013;19:106–111.

  417. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertility and sterility. 2001; 75(5):898-915.

  418. Binder EF, Birge SJ, Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. Journal of the American Geriatrics Society. 1996; 44(3):231-6.

  419. Denke MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolemic postmenopausal women. The American journal of medicine. 1995; 99(1):29-35.

  420. Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. The Australian & New Zealand journal of obstetrics & gynaecology. 2003; 43(3):213-6.

  421. Davidson MH, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolaemia in postmenopausal women. Drugs & aging. 2002; 19(3):169-78.

  422. Lee J-Y, Hyun HS, Park H-G, et al. Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women. Journal of Menopausal Medicine. 2015;21(2):104-111. doi:10.6118/jmm.2015.21.2.104.

  423. Cetinkaya MB, Alper T, Kokcu A, Yanik FF, Malatyalioglu E. Tibolone versus four estrogen replacement therapy protocols and plasma lipid levels in postmenopausal women. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2002; 79(1):17-23.

  424. Bitoska I, Krstevska B, Milenkovic T, et al. Effects of Hormone Replacement Therapy on Insulin Resistance in Postmenopausal Diabetic Women. Open Access Macedonian Journal of Medical Sciences. 2016;4(1):83-88. doi:10.3889/oamjms.2016.024.

  425. Triusu RJ, Cowie CC, Harris MI. Hormone replacement therapy and glucose metabolism. Obstetrics and gynecology. 2000; 96(5 Pt 1):665-70..

  426. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV, . Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes care. 2001; 24(7):1144-50.

  427. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV, . Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes care. 2001; 24(7):1144-50.

  428. Retrieved from http://care.diabetesjournals.org/content/26/4/1088.

  429. Ferrara A et al. Hormone Replacement Therapy Is Associated With Better Glycemic Control in Women With Type 2 Diabetes. Diabetes Care 2001 Jul; 24(7): 1144-1150.

  430. Ferrara A, Karter, AJ, Ackerson LM, Liu JY, Selby JV. Hormone Replacement Therapy Is Associated With Better Glycemic Control in Women With Type 2 Diabetes. Diabetes Care 2001 Jul; 24(7): 1144-1150.

  431. Retrieved from https://www.medscape.com/viewarticle/442148.

  432. Xu Y, Lin J, Wang S, Xiong J, Zhu Q. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. The Kaohsiung journal of medical sciences. 2014; 30(7):350-61.

  433. Retrieved from http://www.thejournalofdiabetesnursing.co.uk/media/content/_master/2956/files/pdf/jdn2-2-39-42.pdf.

  434. Zhang Y, Howard BV, Cowan LD. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. Diabetes care. 2002; 25(3):500-4.

  435. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril. 1993;60:664–667. PMid:8405521.

  436. Ferrara A, Barrett-Connor E, Wingard DL, Edelstein SL. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status:the Rancho Bernardo Study 1984-1987. Diabetes Care. 1995;18:220–225. http://dx.doi.org/10.2337/diacare.18.2.220 . PMid:7729301.

  437. Andersson B, Mattsson LA, Hahn L, Marin P, Lapidus L, Holm G, Bengtsson BA, Bjorntorp P. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Meta. 1997;82:638–643.

  438. Brown MD, Korytkowski MT, Zmuda JM, McCole SD, Moore GE, Hagberg JM. Insulin sensitivity in postmenopausal women:independent and combined associations with hormone replacement, cardiovascular fitness, and body composition. Diabetes Care. 2000;23:1731–1736.

  439. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes:a prospective study. Diabetes Care. 1999;22:1401–1407.

  440. Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 1993;42:846–853.

  441. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Current hypertension reports. 2006; 8(5):368-76.

  442. Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, Rajzer M, Jankowski P. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. Journal of human hypertension. 2002; 16(7):509-16.

  443. McCubbin JA, Helfer SG, Switzer FS, Price TM. Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease. American heart journal. 2002; 143(4):711-7.

  444. Butkevich A, Abraham C, Phillips RA. Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women. American journal of hypertension. 2000; 13(9):1039-41.

  445. Karalis I, Beevers G, Beevers M, Lip G. Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood pressure. 2005; 14(1):38-44.

  446. Kornhauser C, Malacara JM, Garay ME, Perez‐Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J Hum Hypertens 1997; 11: 405–411.

  447. Rajkumar C et al. Hormonal therapy increases arterial compliance in postmenopausal women J Am Coll Cardiol 1997; 30: 350–356

  448. Giraud GD et al. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women Am J Obstet Gynecol 1996; 174: 1708–1716.

  449. Nagai Y et al. Influence of age and postmenopausal estrogen replacement therapy on carotid arterial stiffness in women Cardiovasc Res 1999; 41: 307–311.

  450. Angerer P, Kothny W, StĂ”rk S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial J Am Coll Cardiol 2000; 36: 1789–1796.

  451. Failla M et al. Effects of cigarette smoking on carotid and arterial artery distensibility J Hypertens 1997; 15: 1659–1664.

  452. Kool MJ et al. Short-and long-term effects of smoking on arterial wall properties in habitual smokers J Am Coll Cardiol 1993; 22: 1881–1886.

  453. Gilligan DM et al. Acute vascular effects of estrogen in postmenopausal women Circulation 1994; 90: 786–791.

  454. Howard G et al. for the IRAS Investigators. Insulin sensitivity and atherosclerosis Circulation 1996; 93: 1809–1817.

  455. DeMeersman RE et al. Estrogen replacement, vascular distensibility, and blood pressures in postmenopausal women Am J Physiol 1998; 274: H1539–H1544.

  456. Mendelsohn ME, Karas RH. Mechanisms of disease: the protective effects of estrogen on the cardiovascular system N Engl J Med 1999; 340: 1801–1811.

  457. Lisabeth L, Bushnell C. Menopause and Stroke: An Epidemiologic Review. Lancet neurology. 2012;11(1):82-91. doi:10.1016/S1474-4422(11)70269-1.

  458. Veerus P, Hovi S-L, Fischer K, et al. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757] Maturitas. 2006;55:162–173.

  459. Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas. 2006; 54(1):11-8.

  460. Lobo RA. The risk of stroke in postmenopausal women receiving hormonal therapy. Climacteric : the journal of the International Menopause Society. 2009; 12 Suppl 1:81-5.

  461. Lobo RA. Benefits and risks of estrogen replacement therapy. American journal of obstetrics and gynecology. 1995; 173(3 Pt 2):982-9.

  462. Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climacteric : the journal of the International Menopause Society. 2007; 10 Suppl 2:27-31.

  463. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.

  464. Arana A, Varas C, Gonzalez-Perez A, Gutierrez L, Bjerrum L, Garcia Rodriguez LA. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause. 2006;13:730–736.

  465. Carrasquilla GD, Frumento P, Berglund A. Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies. PLoS medicine. 2017; 14(11):e1002445.

  466. Tsuda K, Kinoshita Y, Kimura K, Nishio I, Masuyama Y. Electron paramagnetic resonance investigation on modulatory effect of 17ÎČ-estradiol on membrane fluidity of erythrocytes in postmenopausal women. Arterioscler Thromb Vasc Biol. 2001; 21: 1306–1312.

  467. Liu F, Yuan R, Benashski SE, McCullough LD. Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab. 2009;29(4):792–802. doi:10.1038/jcbfm.2009.5.

  468. Arnold AP. The organizational-activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm Behav. 2009;55(5):570–8. doi:10.1016/j.yhbeh.2009.03.011.

  469. McCullough LD, Hurn PD. Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol Metab. 2003;14(5):228–35.

  470. Persky RW, Liu F, Xu Y, Weston G, Levy S, Roselli CE, et al. Neonatal testosterone exposure protects adult male rats from stroke. Neuroendocrinology. 2012 doi:10.1159/000343804.

  471. Matthews JR, Hay RT. Regulation of the DNA binding activity of NF-kappa B. Int J Biochem Cell Biol. 1995;27(9):865–79.

  472. Emmanouil M, Taoufik E, Tseveleki V, Vamvakas SS, Probert L. A role for neuronal NF-kappaB in suppressing neuroinflammation and promoting neuroprotection in the CNS. Adv Exp Med Biol. 2011;691:575–81. doi:10.1007/978-1-4419-6612-4_60.

  473. Rupec RA, Baeuerle PA. The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem. 1995;234(2):632–40.

  474. Dudek EJ, Shang F, Taylor A. H(2)O(2)-mediated oxidative stress activates NF-kappa B in lens epithelial cells. Free Radic Biol Med. 2001;31(5):651–8.

  475. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002;298(5596):1241–5. doi:10.1126/science.1071914298/5596/1241.

  476. Carroll JE, Howard EF, Hess DC, Wakade CG, Chen Q, Cheng C. Nuclear factor-kappa B activation during cerebral reperfusion: effect of attenuation with N-acetylcysteine treatment. Brain Res Mol Brain Res. 1998;56(1–2):186–91.

  477. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med. 1999;5(5):554–9. doi:10.1038/8432.

  478. Nurmi A, Lindsberg PJ, Koistinaho M, Zhang W, Juettler E, Karjalainen-Lindsberg ML, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke. 2004;35(4):987–91. doi:10.1161/01.STR.0000120732.45951.26.

  479. Culmsee C, Siewe J, Junker V, Retiounskaia M, Schwarz S, Camandola S, et al. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J Neurosci. 2003;23(24):8586–95.

  480. Hill WD, Hess DC, Carroll JE, Wakade CG, Howard EF, Chen Q, et al. The NF-kappaB inhibitor diethyldithiocarba-mate (DDTC) increases brain cell death in a transient middle cerebral artery occlusion model of ischemia. Brain Res Bull. 2001;55(3):375–86.

  481. Foehr ED, Lin X, O’Mahony A, Geleziunas R, Bradshaw RA, Greene WC. NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. J Neurosci. 2000;20(20):7556–63.

  482. Duckworth EA, Butler T, Collier L, Collier S, Pennypacker KR. NF-kappaB protects neurons from ischemic injury after middle cerebral artery occlusion in mice. Brain Res. 2006;1088(1):167–75. doi:10.1016/j.brainres.2006.02.103.

  483. Sarnico I, Lanzillotta A, Benarese M, Alghisi M, Baiguera C, Battistin L, et al. NF-kappaB dimers in the regulation of neuronal survival. Int Rev Neurobiol. 2009;85:351–62. doi:10.1016/S0074-7742(09)85024-1

  484. Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158(3):995–1006. doi:10.1016/j.neuroscience.2008.07.007.

  485. Xing D, Oparil S, Yu H, Gong K, Feng W, Black J, et al. Estrogen modulates NFkappaB signaling by enhancing IkappaBalpha levels and blocking p65 binding at the promoters of inflammatory genes via estrogen receptor-beta. PLoS One. 2012;7(6):e36890. doi:10.1371/journal.pone.0036890PONE-D-11-18299.

  486. Lian H, Shim DJ, Gaddam SS, Rodriguez-Rivera J, Bitner BR, Pautler RG, et al. IkappaBalpha deficiency in brain leads to elevated basal neuroinflammation and attenuated response following traumatic brain injury: implications for functional recovery. Mol Neurodegener. 2012;7(1):47. doi:10.1186/1750-1326-7-47.

  487. Hurn PD, Macrae IM. Estrogen as neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000; 20: 631–652.

  488. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol. 2001; 63: 29–60.

  489. Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neuroscience. 2000; 18: 347–358.

  490. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M, Rosewewll KL. Estradiol is a protective factor in the adult and aging brain. Brain Res Rev. 2001; 37: 313–319.

  491. Natrajan PK, Gambrell RD. Estrogen replacement therapy in patients with early breast cancer. American journal of obstetrics and gynecology. 2002; 187(2):289-94; discussion 294-5.

  492. Holroyd CR, Edwards CJ. The effects of hormone replacement therapy on autoimmune disease: rheumatoid arthritis and systemic lupus erythematosus. Climacteric : the journal of the International Menopause Society. 2009; 12(5):378-86.

  493. Kumru S, Godekmerdan A, Yilmaz B. Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. Journal of reproductive immunology. 2004; 63(1):31-8.

  494. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB. Immune effects of hormone replacement therapy in post-menopausal women. Experimental gerontology. 2001; 36(2):311-26.

  495. Engelmann F, Rivera A, Park B, Messerle-Forbes M, Jensen JT, Messaoudi I. Impact of Estrogen Therapy on Lymphocyte Homeostasis and the Response to Seasonal Influenza Vaccine in Post-Menopausal Women. PloS one. 2016; 11(2):e0149045.

  496. Ettinger B., Friedman G. D., Bush T., Quesenberry C. P Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet. Gynecol., 87: 6-12, 1996.

  497. Kreuzer M., Gerken M., Henirich J., Kreienbrock L., Wichman H-E. Hormonal factors and risk of lung cancer among women?. Int. J. Epidemiol., 32: 263-271, 2003.

  498. Olsson H., Bladstrom A., Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy?. Obstet. Gynecol., 102: 565-570, 2003.

  499. Campagnoli C., Biglia N., Altare F., Lanza M. G., Lesca L., Cantamessa C., Peris C., Fiorucci G. C., Sismondi P. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol. 0Endocrinol., 7: 251-258, 1993.

  500. Sakiani S, Olsen NJ, Kovacs WJ. Gonadal steroids and humoral immunity. Nat. Rev. Endocrinol. 2013;9:56–62.

  501. Regan JC, Partridge L. Gender and longevity: why do men die earlier than women? Comparative and experimental evidence. Best Pract. Res. Clin. Endocrinol. Metab. 2013;27:467–479.

  502. Carlsten H, D’Elia HF, Erlandsson M, Islander U. Menopause and hormone replacement therapy: effects on the immune system, arthritis and bone. Arthritis Research & Therapy. 2004;6(Suppl 3):36. doi:10.1186/ar1371.

  503. Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB. Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol. 2001;36:311–326.

  504. Deguchi K, Kamada M, Irahara M, Maegawa M, Yamamoto S, et al. Postmenopausal changes in production of type 1 and type 2 cytokines and the effects of hormone replacement therapy. Menopause. 2001;8:266–273.

  505. Saucedo R, Rico G, Basurto L, Ochoa R, Zarate A. Transdermal estradiol in menopausal women depresses interleukin-6 without affecting other markers of immune response. Gynecol Obstet Invest. 2002;53:114–117.

  506. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006;54:298–302.

  507. Shimoya K, Zhang Q, Temma K, Kimura T, Tsujie T, et al. Secretory leukocyte protease inhibitor levels in cervicovaginal secretion of elderly women. Maturitas. 2006;54:141–148.

  508. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.

  509. Braendle W , Kuhl H. Stellungnahme zur Millionen-Frauenstudie und Brustkrebs. J Menopause. 2003;3:3–4.

  510. Goodman N, Goldzieher J, Ayala C. Critique of the report from the writing group of the WHI. Menopausal Med. 2003;10:1–4.

  511. Machens K., Schmidt-Gollwitzer K. Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod. 2003;18:1992–9.

  512. McDonough P. G. The randomized world is not without its imperfections: reflections on the Women’s Health Initiative Study. Fertil Steril. 2002;78:951–6.

  513. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric. 2003;6:302–10; discussion 310-3.

  514. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523-34.

  515. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.

  516. Oriba HA, Maibach HI. Vulvar transepidermal water loss (TEWL) decay curves. Effect of occlusion, delipidation, and age. Acta Derm Venereol. 1989;69(6):461-5.

  517. Naftolin F., Taylor H. S., Karas R., Brinton E., Newman I., Clarkson T. B., Mendelsohn M., Lobo R. A., Judelson D. R., Nachtigall L. E., Heward C. B., Hecht H., Jaff M. R., Harman S. M. The Women’s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004;81:1498–501.

Other Peptides

LL-37

Zinc-Thymulin

Tesamorelin

Ipamorelin

NMN (Nicotinamide Mononucleotide)

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer

See All Men’s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

GenemedicsÂź Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

 Our Locations

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background